US20100167267A1 - Mass Spectrometric Quantitation - Google Patents

Mass Spectrometric Quantitation Download PDF

Info

Publication number
US20100167267A1
US20100167267A1 US12/530,747 US53074708A US2010167267A1 US 20100167267 A1 US20100167267 A1 US 20100167267A1 US 53074708 A US53074708 A US 53074708A US 2010167267 A1 US2010167267 A1 US 2010167267A1
Authority
US
United States
Prior art keywords
mass
analyte
sample
labels
labelled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/530,747
Other languages
English (en)
Inventor
Peter Schulzknappe
Ian Pike
Karsten Kuhn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Electrophoretics Ltd
Original Assignee
Electrophoretics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Electrophoretics Ltd filed Critical Electrophoretics Ltd
Publication of US20100167267A1 publication Critical patent/US20100167267A1/en
Assigned to ELECTROPHORETICS LIMITED reassignment ELECTROPHORETICS LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCHULZKNAPPE, PETER, PIKE, IAN, KUHN, KARSTEN
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/0009—Calibration of the apparatus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N2001/2893—Preparing calibration standards
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
    • G01N2333/765—Serum albumin, e.g. HSA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]

Definitions

  • This invention relates to mass spectrometry methods of assaying for an analyte by labelling test samples and calibration samples with isobaric mass labels. Relative and/or absolute quantitation of the analytes of interest is particularly facilitated by the invention.
  • Indirect detection means that an associated label molecule can be used to identify the original analyte, where the label is designed for sensitive detection and a simple mass spectrum.
  • Simple mass spectra mean that multiple labels can be used to analyse multiple analytes simultaneously.
  • PCT/GB98/00127 describes arrays of nucleic acid probes covalently attached to cleavable labels that are detectable by mass spectrometry which identify the sequence of the covalently linked nucleic acid probe.
  • the labelled probes of this application have the structure Nu-L-M where Nu is a nucleic acid covalently linked to L, a cleavable linker, covalently linked to M, a mass label.
  • Preferred cleavable linkers in this application cleave within the ion source of the mass spectrometer.
  • Preferred mass labels are substituted poly-aryl ethers.
  • This application discloses a variety of ionisation methods and analysis by quadrupole mass analysers, TOF analysers and magnetic sector instruments as specific methods of analysing mass labels by mass spectrometry.
  • PCT/GB94/01675 discloses ligands, and specifically nucleic acids, cleavably linked to mass tag molecules. Preferred cleavable linkers are photo-cleavable.
  • MALDI Matrix Assisted Laser Desorption Ionisation
  • TOF Time of Flight
  • PCT/US97/22639 discloses releasable non-volatile mass-label molecules.
  • these labels comprise polymers, typically biopolymers which are cleavably attached to a reactive group or ligand, i.e. a probe.
  • Preferred cleavable linkers appear to be chemically or enzymatically cleavable.
  • MALDI TOF mass spectrometry as a specific method of analysing mass labels by mass spectrometry.
  • PCT/US97/01070, PCT/US97/01046, and PCT/US97/01304 disclose ligands, and specifically nucleic acids, cleavably linked to mass tag molecules.
  • Preferred cleavable linkers appear to be chemically or photo-cleavable.
  • Two samples can be compared quantitatively by labelling one sample with the biotin linker and labelling the second sample with a deuterated form of the biotin linker.
  • Each peptide in the samples is then represented as a pair of peaks in the mass spectrum. Integration of the peaks in the mass spectrum corresponding to each tag indicates the relative expression levels of the peptide linked to the tags.
  • PCT/GB01/01122 discloses a set of two or more mass labels, each label in the set comprising a mass marker moiety attached via a cleavable linker to a mass normalisation moiety, the mass marker moiety being fragmentation resistant.
  • the aggregate mass of each label in the set may be the same or different and the mass of the mass marker moiety of each label in the set may be the same or different.
  • each label has an aggregate mass different from all other labels in that group, and in any group of labels within the set having a common aggregate mass each label has a mass marker moiety having a mass different from that of all other mass marker moieties in that group, such that all of the mass labels in the set are distinguishable from each other by mass spectrometry.
  • This application also discloses an array of mass labels, comprising two or more sets of mass labels as defined above. The aggregate mass of each of the mass labels in any one set is different from the aggregate mass of each of the mass labels in every other set in the array.
  • This application further discloses methods of analysis comprising detecting an analyte by identifying by mass spectrometry a mass label or a combination of mass labels unique to the analyte.
  • Preferred mass labels have the structure M-L-X, where M is the mass normalization group, L is the cleavable linker and X is the mass marker moiety. The nature of M and X is not particularly limited.
  • PCT/GB02/04240 discloses a set of two or more mass labels, each label in the set comprising a mass marker moiety attached via at least one amide bond to a mass normalisation moiety.
  • the mass marker moiety comprises an amino acid and the mass normalisation moiety comprises an amino acid.
  • the aggregate mass of each label in the set may be the same or different and the mass of the mass marker moiety of each label in the set may be the same or different such that all of the mass labels in the set are distinguishable from each other by mass spectrometry.
  • this application also discloses an array of mass labels and a method of analysis. This application is specifically directed to the analysis of peptides and mass labels with mass normalisation moieties and mass marker moieties comprising at least one amino acid.
  • the reference peptide will produce a distinct peak from the naturally occurring form of the peptide in the sample of interest.
  • the AQUA peptide mass will be separated by an increased mass of about 5-50 daltons compared to the natural peptide.
  • AQUA is able to measure absolute quantities of multiple proteins in a single experiment, it is not suitable for development of reference standard curves to cover a range of naturally occurring concentrations. For biomarker validation studies this may be problematic since regulation of protein expression may result in a ten-fold or greater range of concentrations for a given protein. Using a single reference standard may lead to inaccurate quantitation of natural peptide levels at the extremes of regulation and it would be desirable to provide a means of including readily distinguishable reference peptides at several different concentrations to cover the physiological range and which provide an appropriate standard curve against which the level of the target peptide in a sample can be read. Producing such curves using AQUA would be difficult since each added peptide increases the complexity of the MS profile. In addition, to ensure that the standard curve is built only on the reference peptides it would be advisable if not essential to perform sequence confirmation by MS/MS of each reference peptide as well as for the target peptide in the sample.
  • the inventors have developed a method of quantifying molecules of interest using isobarically tagged reference biomolecules or complex biological materials, for example peptides, that allow construction of multi-point standard curves for each analyte without increasing MS complexity.
  • the present invention provides a method of assaying for an analyte, which method comprises:
  • the different aliquots each have a known quantity of the analyte.
  • known quantity means that the absolute quantity, or a qualitative quantity of the analyte in each aliquot of the calibration sample is known.
  • a qualitative quantity in the present context means a quantity which is not known absolutely, but may be a range of quantities that are expected in a subject having a particular state, for example a subject in a healthy or diseased state, or some other expected range depending on the type of test sample under investigation.
  • Each aliquot is “different” since it contains a different quantity of the analyte. Typically this is achieved by taking different volumes from a standard sample, especially for qualitative quantities where taking different volumes will ensure that different quantities are present in each aliquot in a desired ratio, without needing to know the absolute quantities.
  • step (b) comprises:
  • the fragmentation is caused by Collision Induced Dissociation (CID), Surface Induced Dissociation (SID), Electron Capture Dissociation (ECD), Electron Transfer Dissociation (ETD), or Fast Atom Bombardment.
  • CID Collision Induced Dissociation
  • SID Surface Induced Dissociation
  • ECD Electron Capture Dissociation
  • ETD Electron Transfer Dissociation
  • Electron capture dissociation is a method of fragmenting multiply charged (protonated) peptide or proteins ions for tandem mass spectrometric analysis (structural elucidation).
  • multiply protonated peptide or proteins are confined in the Penning trap of a Fourier transform ion cyclotron resonance (FTICR) mass spectrometer and exposed to electrons with near-thermal energies.
  • FTICR Fourier transform ion cyclotron resonance
  • one or more protein cations can be neutralized with low energy electrons to cause specific cleavage of bonds to form c, z products, in contrast to b, y products formed by other techniques such as collisionally activated dissociation (CAD; also known as collision-induced dissociation, CID).
  • CAD collisionally activated dissociation
  • thermal electrons introduced into the RF fields of RF 3D quadrupole ion trap (QIT), quadrupole time-of-flight, or RF linear 2D quadrupole ion trap (QLT) instruments maintain their thermal energy only for a fraction of a microsecond and are not trapped in these devices, ECD remains a technique exclusively used with FTICR, the most expensive type of MS instrumentation.
  • Electron transfer dissociation is a method of fragmenting multiply protonated peptide or proteins ions for tandem mass spectrometric analysis (structural elucidation). Similar to electron capture dissociation (ECD), ETD induces fragmentation of cations (e.g. multiple charged peptide or proteins) by transferring electrons to them. In contrast to ECD, ETD does not use free electrons but employs radical anions for this purpose (e.g. anthracene or azobenzene anions which possess sufficiently low electron affinities to act as electron donors).
  • radical anions e.g. anthracene or azobenzene anions which possess sufficiently low electron affinities to act as electron donors.
  • ETD After the electron transfer, ETD results in a similar fragmentation pattern as ECD, i.e. the formation of so called c and z ions.
  • ETD can be implemented on various “lower cost” mass spectrometers like quadrupole ion trap (QIT) or RF linear 2D quadrupole ion trap (QLT) instruments which are not appropriate for ECD.
  • QIT quadrupole ion trap
  • QLT RF linear 2D quadrupole ion trap
  • the most preferred embodiment is where the fragmentation is caused by collision-induced dissociation. Collision-induced dissociation occurs during an MS/MS experiment.
  • MS/MS in the context of mass spectrometry refers to an experiment which involves selecting ions, subjecting selected ions to CID and subjecting the fragment ions to further analysis.
  • This method enables multi-point calibration of the quantity of each analyte without increasing MS complexity.
  • Analyte quantitation is obtained in the MS/MS profile, and the analyte in the sample and in the calibration sample can be simultaneously quantified and identified by tandem mass spectrometry.
  • This method provides means for the measurement of up to 10, up to 20, up to 50 or more analytes in a single LC-MS/MS experiment.
  • the method may comprise a further step prior to step (a) of differentially labelling each test sample or each aliquot of the calibration sample with one or more isobaric mass labels.
  • the method also comprises a further step of combining the differentially labelled aliquots to produce a calibration sample prior to step (a).
  • the test sample may comprise a plurality of different analytes, and in this case a calibration sample is provided for each different analyte, and step (b) is repeated for each different analyte.
  • the plurality of analytes are peptide fragments of a protein or polypeptide which are produced by chemical or enzymatic processing of the protein or polypeptide prior to step (a).
  • the plurality of analytes are peptides from the same protein or polypeptide.
  • a plurality of test samples is assayed for an analyte.
  • each of the plurality of test samples is assayed for the same analyte.
  • each of the test samples may be differentially labelled with one or more isobaric mass labels and combined with a single calibration sample in step (a), and the quantity of the analyte in each sample is determined simultaneously in step (b).
  • each test sample is labelled with the same mass label, and steps (a) and (b) are repeated for each different sample, The same calibration sample can be used for each test sample to be assayed.
  • the same known volume of the calibration sample comprising at least two aliquots of the analyte is added to each different test sample. This method is particularly useful in clinical studies involving multiple samples from patients. If a large quantity of the calibration sample is prepared and fractions taken, the same calibration sample can be used by multiple laboratories, facilitating cross-study and cross-laboratory comparisons.
  • the quantity of analyte in each aliquot in the calibration sample is a known absolute quantity. This allows for the absolute quantity of an analyte in a test sample to be determined in step (b).
  • the absolute quantity of an analyte in each aliquot in the calibration sample is not known.
  • the quantity of analyte in each aliquot in the calibration sample is a known qualitative quantity.
  • the calibrating step comprises calibrating the quantity of the analyte in the test sample against the qualitative and determined quantities of the analytes in the aliquots of the calibration sample.
  • the qualitative quantity is an expected range of quantities of analyte in a subject having a particular state, such as a healthy or diseased state.
  • the quantity of analyte in each different aliquot is selected to reflect the known or suspected variation in the quantity of the analyte in the test sample.
  • aliquots are provided which correspond to the upper and lower limits, and optionally intermediate points within a range of the known or suspected quantities of the analyte found in test samples of healthy or diseased subjects.
  • the different quantities of analyte present in the different aliquots may correspond to the known or suspected quantity of analyte present in a test sample which has been incubated for different periods of time.
  • the calibration sample may comprise an analyte in a quantity that indicates the presence and/or stage of a particular disease.
  • the calibration sample may also comprise the analyte in a quantity which indicates the efficacy and/or toxicity of a therapy.
  • the method according to the present invention may comprise a further step of separating the components of the samples prior to step (a).
  • the method may also comprise a step of digesting each sample with at least one enzyme to digest components of the samples prior to step (a).
  • the samples are labelled with the isobaric mass labels prior to digestion.
  • the labeling step occurs after the digestion step.
  • the enzyme digestion step may also occur after step (a) but before step (b).
  • the mass labels used in the method further comprise an affinity capture ligand.
  • the affinity capture ligand of the mass label binds to a counter-ligand so as to separate the isobarically labeled analytes from the unlabelled analytes after step (a) but before step (b).
  • the affinity capture ligand provides a means of enrichment of the analytes of interest, thereby increasing analytical sensitivity.
  • the method according to the invention may further include the step of separating the isobarically labeled analytes electrophoretically or chromatographically after step (a) but before step (b).
  • the mass label comprises the following structure:
  • X is a mass marker moiety
  • L is a cleavable linker
  • M is a mass normalisation moiety.
  • L may be a single bond, or part of X, or part of M.
  • These mass labels may be attached at any point to the analyte in the test or calibration samples, e.g. through M, L or X. Preferably, they are attached through M, e.g. the label would comprise the structure:
  • This is typically effected by including a reactive functionality in the mass label to allow it to bind to the analyte, e.g:
  • the labels comprise a reactive functionality these are termed reactive mass labels.
  • each Z is independently N, N(R 1 ), C(R 1 ), CO, CO(R 1 ) (i.e. —O—C(R 1 )— or C(R 1 )—O—), C(R 1 ) 2 , O or S;
  • X is N, C or C(R 1 ); each R 1 is independently H, a substituted or unsubstituted straight or branched C 1 -C 6 alkyl group, a substituted or unsubstituted aliphatic cyclic group, a substituted or unsubstituted aromatic group or a substituted or unsubstituted heterocyclic group; and y is an integer from 0-10.
  • the reactive functionality for attaching the mass label to the analyte is not especially limited and may comprise any appropriate reactive group.
  • mass label used in the present context is intended to refer to a moiety suitable to label an analyte for determination.
  • label is synonymous with the term tag.
  • mass marker moiety used in the present context is intended to refer to a moiety that is to be detected by mass spectrometry.
  • mass marker moiety is synonymous with the term mass marker group or the term reporter group.
  • mass normalisation moiety used in the present context is intended to refer to a moiety that is not necessarily to be detected by mass spectrometry, but is present to ensure that a mass label has a desired aggregate mass.
  • the mass normalisation moiety is not particularly limited structurally, but merely serves to vary the overall mass of the mass label.
  • each R 1 on the carbon atom may be the same or different (i.e. each R 1 is independent).
  • the C(R 1 ) 2 group includes groups such as CH(R 1 ), wherein one R 1 is H and the other R 1 is another group selected from the above definition of R 1 .
  • the bond between X and the non-cyclic Z may be single bond or a double bond depending upon the selected X and Z groups in this position.
  • the bond from X to the non-cyclic Z must be a single bond.
  • the bond from X to the non-cyclic Z may be a single bond or a double bond depending upon the selected non-cyclic Z group and cyclic Z groups.
  • the non-cyclic Z group is N or C(R 1 ) the bond from non-cyclic Z to X is a single bond or if y is 0 may be a double bond depending on the selected X group and the group to which the non-cyclic Z is attached.
  • the bond to X must be a single bond.
  • the person skilled in the art may easily select suitable X, Z and (CR 1 2 ) y groups with the correct valencies (single or double bond links) according to the above formula.
  • the present inventors have discovered that the mass labels defined above can be easily identified in a mass spectrometer and also allow sensitive quantification.
  • the aggregate molecular weight of the mass label is 600 Daltons or less, more preferably 500 Daltons or less, still more preferably 400 Daltons or less, most preferably from 300 to 400 Daltons.
  • Particularly preferred molecular weights of the mass labels are 324, 338, 339 and 380 Daltons. These preferred embodiments are particularly advantageous because the small size of the mass labels means that the size of the peptide to be detected is minimally increased when labelled with the mass label. Therefore, the peptide labelled with the mass label may be viewed in the same mass spectrum window as unlabelled peptide when analysed by mass spectroscopy. This facilitates identification of peaks from the mass label itself.
  • the molecular weight of the mass marker moiety is 300 Daltons or less, preferably 250 Daltons or less, more preferably 100 to 250 Daltons, most preferably 100-200 Daltons.
  • these preferred embodiments are particularly advantageous because the small size of the mass marker moiety means that it produces a peak in the silent region of a mass spectrum, which allows the mass marker to be easily identified from the mass spectrum and also allows sensitive quantification.
  • silent region of a mass spectrum (such as an MS/MS spectrum) used in the present context is intended to refer to the region of a mass spectrum with low background “noise” caused by peaks relating to the presence of fragments generated by fragmentation of the labelled peptides.
  • An MS/MS spectrum is obtained by the fragmentation of one peak in MS-mode, such that no contaminants, such as buffering reagents, denaturants and detergent should appear in the MS/MS spectrum. In this way, quantification in MS/MS mode is advantageous.
  • the term silent region is intended to refer to the region of the mass spectrum with low “noise” caused by peaks relating to the peptide to be detected. For a peptide or protein, the silent region of the mass spectrum is less than 200 Daltons.
  • the present inventors have also discovered that the reactive mass labels defined above are easily and quickly reacted with a protein to form a labelled protein.
  • each label in the set is as defined above and wherein each mass normalisation moiety ensures that a mass label has a desired aggregate mass, and wherein the set comprises: mass labels having a mass marker moiety, each mass marker moiety having a mass different from that of all other mass marker moieties in the set, and each label in the set having a common aggregate mass; and wherein all the mass labels in the set are distinguishable from each other by mass spectroscopy.
  • isobaric means that the mass labels have substantially the same aggregate mass as determined by mass spectrometry. Typically, the average molecular masses of the isobaric mass labels will fall within a range of ⁇ 0.5 Da of each other.
  • labels shall be synonymous with the term “tags”. In the context of the present invention, the skilled addressee will understand that the term “mass marker moiety” and the term “reporter group” can be used interchangeably.
  • the number of labels in the set is not especially limited, provided that the set comprises a plurality of labels. However, it is preferred if the set comprises two or more, three or more, four or more, or five or more labels, more preferably six or more labels, most preferably eight or more labels.
  • aggregate mass in the present context refers to the total mass of the mass label, i.e. the sum of the masses of the mass marker moiety, the cleavable linker, the mass normalisation moiety and any other components of the mass label.
  • the mass of the mass normalisation moiety will be different in each mass label in the set.
  • the mass of the mass normalisation moiety in each individual mass label will be equal to the common aggregate mass minus the mass of the particular mass marker moiety in that mass label and minus the mass of the cleavable linker.
  • mass labels in the set are distinguishable from each other by mass spectroscopy. Therefore, a mass spectrometer can discriminate between the mass labels, i.e. the peaks derived from individual mass labels can be clearly separated from one another.
  • the difference in mass between the mass marker moieties means that a mass spectrometer can discriminate between ions derived from different mass labels or mass marker moieties.
  • the present invention may also employ an array of mass labels, comprising two or more sets of mass labels as defined above, wherein the aggregate mass of each of the mass labels in any one set is different from the aggregate mass of each of the mass labels in every other set in the array.
  • the array of mass labels are preferably all chemically identical (substantially chemically identical).
  • substantially chemically identical means that the mass labels have the same chemical structure, into which particular isotopic substitutions may be introduced or to which particular substituents may be attached.
  • the mass labels may comprise a sensitivity enhancing group.
  • the mass labels are preferably of the form:
  • the sensitivity enhancing group is usually attached to the mass marker moiety, since it is intended to increase the sensitivity of the detection of this moiety in the mass spectrometer.
  • the reactive functionality is shown as being present and attached to a different moiety than the sensitivity enhancing group.
  • the mass labels need not be limited in this way and in some cases the sensitivity enhancing group may be attached to the same moiety as the reactive functionality.
  • the present invention provides a method of assaying a low abundance analyte in a sample, which method comprises the method of mass spectrometric analysis as defined above, wherein the calibration sample comprises a large quantity of the analyte to be assayed, and the sample may comprise the analyte in low abundance.
  • the analyte is present in the calibration sample in a quantity such that it can be readily detected and separated together with the analyte in the sample by a method such as one or two-dimensional gel electrophoresis, free-flow electrophoresis, capillary electrophoresis, off-gel isoelectric focusing or liquid chromatography mass spectrometry prior to step (b).
  • the analyte in the sample is a protein
  • the analyte in the calibration sample is a recombinant form of the protein in the sample.
  • FIG. 1 shows a schematic of a method according to the present invention.
  • FIG. 2 shows the MS/MS profile of one BSA tryptic peptide.
  • Upper panel shows the full MS/MS spectrum.
  • Lower panel shows an expansion of the isobaric mass marker moiety region, the different intensities reflecting different abundances of the same peptide in the study sample (126) and calibration sample (128, 129, 130, 131).
  • FIG. 3 shows the four point calibration curve for a set of isobarically-labelled bovine serum albumin aliquots in a calibration sample.
  • FIG. 4 shows a schematic of a method of preparing a plasma sample for use in the present invention.
  • FIG. 5 shows a schematic of a method according to the present invention wherein prior to mass spectrometry analysis a mixture comprising a sample and a calibration sample is run on a 1D PAGE gel, and an appropriate spot on the gel is picked and digested.
  • FIG. 6 shows a schematic of a method according to the present invention for assaying an analyte in a plurality of samples.
  • FIG. 7 shows an accumulated MS from the retention profile of a labelled peptide from clusterin as described in Example 3 below. Inset-zoom view of m/z region 915-935 showing the peptide of interest.
  • FIG. 8 shows an accumulated MS/MS spectrum of the labelled peptide from clusterin. Insert: Zoom view at the mass marker region.
  • FIG. 9 shows a calibration curve of the chosen clusterin peptide.
  • FIG. 10 shows a MALDI MS/MS spectrum of peptide FQVDNNNR as described in Example 4 below.
  • FIG. 11 shows a MALDI MS/MS spectrum of peptide GAYPLSIEPIGVR as described in Example 4 below.
  • FIG. 12 shows a MALDI MS/MS spectrum of peptide GQYCYELDEK as described in Example 4 below.
  • This invention provides useful reagents for determining relative and/or absolute quantities of analytes such as peptides, proteins, nucleotides and nucleic acids and means of their production. Specifically this invention relates to isobarically labelled analytes and/or calibration samples for detection by tandem mass spectrometry and associated methods of analysing test samples into which such calibration samples have been added. Relative and/or absolute quantitation of the analytes is particularly facilitated by the invention.
  • This invention provides new methods for assaying analytes by mass spectrometry in a variety of settings including measurement of protein, lipid, carbohydrate and nucleic acid changes in cells, tissues and fluids in human, veterinary, plant, microbial, pharmaceutical, environmental and security sciences.
  • the quantity of the analyte in the test sample and in each aliquot of the calibration sample is determined by mass spectrometry.
  • a calibration function is used to relate the quantity of the analyte in the test sample as measured by mass spectrometry to the actual quantity of the analyte in the test sample.
  • This calibration function uses the quantities of the analyte in each aliquot of the calibration sample (both the actual quantities in the aliquots prior to analysis and the corresponding quantities as measured by mass spectrometry) as variables.
  • the method comprises a step of plotting a graph of the quantity of the analyte in each aliquot versus the quantity of the analyte in each aliquot as determined by mass spectrometry.
  • This step may instead simply involve calculation.
  • the quantity of the analyte in the sample is then calculated by measuring the quantity in the sample as determined by mass spectrometry against the calibration graph.
  • a reference to “a quantity as measured by mass spectrometry” is typically an ion abundance, ion intensity, or other signal measured by mass spectrometry which relates to the quantity of an analyte.
  • the method comprises:
  • the method comprises the steps of:
  • mass spectrometry shall include any type of mass spectrometry capable of fragmentation analysis.
  • the mass spectrometers suitable for use in the present invention include instruments that comprise any form of MS/MS analyser such as a triple quadropole mass spectrometer equipped with a collision chamber, an ion trap mass spectrometer capable of fragmenting selected precursor ions by fast atom bombardment, collision induced dissociation, electron transfer dissociation or any other form of parent ion fragmentation, and matrix assisted laser desorption/ionisation (MALDI) mass spectrometers fitted with a dual time of flight (TOF/TOF) analyser and a means of parent ion fragmentation.
  • TOF/TOF dual time of flight
  • the step of selecting the ions of a predetermined mass to charge ratio is performed in the first mass analyser of a serial instrument.
  • the selected ions are then channeled into a separate collision cell where they are collided with a gas or a solid surface.
  • the collision products are then channeled into a further mass analyser of a serial instrument to detect collision products.
  • Typical serial instruments include triple quadrupole mass spectrometers, tandem sector instruments and quadrupole time of flight mass spectrometers.
  • the step of selecting the ions of a predetermined mass to charge ratio, the step of colliding the selected ions with a gas and the step of detecting the collision products are performed in the same zone of the mass spectrometer. This may be effected in ion trap mass analysers and Fourier Transform Ion Cyclotron Resonance mass spectrometers, for example.
  • MALDI matrix assisted laser desorption/ionisation
  • MALDI requires that the biomolecule solution be embedded in a large molar excess of a photo-excitable ‘matrix’.
  • the application of laser light of the appropriate frequency results in the excitation of the matrix which in turn leads to rapid evaporation of the matrix along with its entrapped biomolecule.
  • Proton transfer from the acidic matrix to the biomolecule gives rise to protonated forms of the biomolecule which can be detected by positive ion mass spectrometry, particularly by Time-Of-Flight (TOF) mass spectrometry.
  • TOF Time-Of-Flight
  • Negative ion mass spectrometry is also possible by MALDI TOF.
  • This technique imparts a significant quantity of translational energy to ions, but tends not to induce excessive fragmentation despite this.
  • the laser energy and the timing of the application of the potential difference used to accelerate the ions from the source can be used to control fragmentation with this technique.
  • This technique is highly favoured due to its large mass range, due to the prevalence of singly charged ions in its spectra and due to the ability to analyse multiple peptides simultaneously.
  • the TOF/TOF technique may be employed in the present invention.
  • the photo-excitable matrix comprises a ‘dye’, i.e. a compound that strongly absorbs light of a particular frequency, and which preferably does not radiate that energy by fluorescence or phosphorescence but rather dissipates the energy thermally, i.e. through vibrational modes. It is the vibration of the matrix caused by laser excitation that results in rapid sublimation of the dye, which simultaneously takes the embedded analyte into the gas phase.
  • a ‘dye’ i.e. a compound that strongly absorbs light of a particular frequency, and which preferably does not radiate that energy by fluorescence or phosphorescence but rather dissipates the energy thermally, i.e. through vibrational modes. It is the vibration of the matrix caused by laser excitation that results in rapid sublimation of the dye, which simultaneously takes the embedded analyte into the gas phase.
  • MALDI techniques are useful in the context of the present invention, the invention is not limited to this type of technique, and other techniques common to the art can be employed by the skilled person in the present invention, if desired.
  • electrospray or nanoelectrospray mass spectrometry may be employed.
  • analyte is not particularly limiting, and the methods according to the present invention may be employed to assay any type of molecule provided that it can be analysed by mass spectrometry, and is capable of being labelled by an isobaric mass label with a mass spectrometrically distinct mass marker group.
  • Analytes include amino acids, peptides, polypeptides, proteins, glycoproteins, lipoproteins, nucleic acids, polynucleotides, oligonucleotides, DNA, RNA, peptide-nucleic acids, sugars, starches and complex carbohydrates, fats and complex lipids, polymers and small organic molecules such as drugs and drug-like molecules.
  • the analyte is a peptide, protein, nucleotide or nucleic acid.
  • protein shall encompass any molecule comprising two or more amino acids including di-peptides, tri-peptides, peptides, polypeptides and proteins.
  • nucleic acid shall encompass any molecule comprising two or more nucleotide bases including di-nucleotides, tri-nucleotides, oligonucleotides, deoxyribonucleic acids, ribonucleic acids and peptide nucleic acids.
  • analyte shall be synonymous with the term biomolecule.
  • isobaric mass label is not particularly limiting.
  • Various suitable isobaric mass labels are known in the art such as Tandem Mass Tags (Thompson et al., 2003, Anal. Chem. 75(8): 1895-1904 (incorporated herein by reference) disclosed in WO 01/68664 (incorporated herein by reference) and WO 03/025576 (incorporated herein by reference), iPROT tags disclosed in U.S. Pat. No. 6,824,981 (incorporated herein by reference) and iTRAQ tags (Pappin et al., 2004, Methods in Clinical Proteomics Manuscript M400129-MCP200 (incorporated herein by reference)). Any of these isobaric mass labels are suitable for preparation of the samples and calibration samples and performing the methods of the current invention.
  • the present invention uses a mass label as defined above wherein the molecular weight of the mass marker moiety is 300 Daltons or less, preferably 250 Daltons or less, more preferably 100 to 250 Daltons, most preferably 100-200 Daltons.
  • Particularly preferred molecular weights of the mass marker moiety are 125, 126, 153 and 154 Daltons, or weights in which one or more or all of the 12C atoms are replaced by 13C atoms, e.g.
  • masses for a non-substituted mass marker moiety having a weight of 125 masses for its substituted counterparts would be 126, 127, 128, 129, 130 and 131 Daltons for substitution with 1, 2, 3, 4, 5 and 6 13C atoms respectively and/or one or more or all of the 14N atoms are replaced by 15N atoms.
  • the components of the mass marker moiety of this invention are preferably fragmentation resistant so that the site of fragmentation of the markers can be controlled by the introduction of a linkage that is easily broken by Collision Induced Dissociation (CID), Surface Induced Dissociation, Electron Capture Dissociation (ECD), Electron Transfer Dissociation (ETD), or Fast Atom Bombardment.
  • CID Collision Induced Dissociation
  • ECD Electron Capture Dissociation
  • ETD Electron Transfer Dissociation
  • Fast Atom Bombardment the linkage is easily broken by CID.
  • the mass marker moiety used in the present invention typically comprises the following group:
  • each Z is independently N, N(R 1 ), C(R 1 ), CO, CO(R 1 ) (i.e. —O—C(R 1 )— or —C(R 1 )—O—), C(R 1 ) 2 , O or S;
  • X is N, C or C(R 1 ); each R 1 is independently H, a substituted or unsubstituted straight or branched C 1 -C 6 alkyl group, a substituted or unsubstituted aliphatic cyclic group, a substituted or unsubstituted aromatic group or a substituted or unsubstituted heterocyclic group; and y is an integer from 0-10.
  • the substituents of the mass marker moiety are not particularly limited and may comprise any organic group and/or one or more atoms from any of groups IIIA, IVA, VA, VIA or VIIA of the Periodic Table, such as a B, Si, N, P, O, or S atom or a halogen atom (e.g. F, Cl, Br or I).
  • groups IIIA, IVA, VA, VIA or VIIA of the Periodic Table such as a B, Si, N, P, O, or S atom or a halogen atom (e.g. F, Cl, Br or I).
  • the organic group preferably comprises a hydrocarbon group.
  • the hydrocarbon group may comprise a straight chain, a branched chain or a cyclic group. Independently, the hydrocarbon group may comprise an aliphatic or an aromatic group. Also independently, the hydrocarbon group may comprise a saturated or unsaturated group.
  • the hydrocarbon when the hydrocarbon comprises an unsaturated group, it may comprise one or more alkene functionalities and/or one or more alkyne functionalities. When the hydrocarbon comprises a straight or branched chain group, it may comprise one or more primary, secondary and/or tertiary alkyl groups. When the hydrocarbon comprises a cyclic group it may comprise an aromatic ring, an aliphatic ring, a heterocyclic group, and/or fused ring derivatives of these groups.
  • the cyclic group may thus comprise a benzene, naphthalene, anthracene, indene, fluorene, pyridine, quinoline, thiophene, benzothiophene, furan, benzofuran, pyrrole, indole, imidazole, thiazole, and/or an oxazole group, as well as regioisomers of the above groups.
  • the number of carbon atoms in the hydrocarbon group is not especially limited, but preferably the hydrocarbon group comprises from 1-40 C atoms.
  • the hydrocarbon group may thus be a lower hydrocarbon (1-6 C atoms) or a higher hydrocarbon (7 C atoms or more, e.g. 7-40 C atoms).
  • the number of atoms in the ring of the cyclic group is not especially limited, but preferably the ring of the cyclic group comprises from 3-10 atoms, such as 3, 4, 5, 6 or 7 atoms.
  • the groups comprising heteroatoms described above, as well as any of the other groups defined above, may comprise one or more heteroatoms from any of groups IIIA, IVA, VA, VIA or VIIA of the Periodic Table, such as a B, Si, N, P, O, or S atom or a halogen atom (e.g. F, Cl, Br or I).
  • the substituent may comprise one or more of any of the common functional groups in organic chemistry, such as hydroxy groups, carboxylic acid groups, ester groups, ether groups, aldehyde groups, ketone groups, amine groups, amide groups, imine groups, thiol groups, thioether groups, sulphate groups, sulphonic acid groups, and phosphate groups etc.
  • the substituent may also comprise derivatives of these groups, such as carboxylic acid anhydrydes and carboxylic acid halides.
  • any substituent may comprise a combination of two or more of the substituents and/or functional groups defined above.
  • the cleavable linker of the mass label used in the present invention is not especially limited.
  • the cleavable linker is a linker cleavable by Collision Induced Dissociation, Surface Induced Dissociation, Electron Capture Dissociation (ECD), Electron Transfer Dissociation (ETD), or Fast Atom Bombardment.
  • the linkage is cleavable by CID.
  • the linker may comprise an amide bond.
  • linker groups which may be used to connect molecules of interest to the mass label compounds used in this invention.
  • a variety of linkers is known in the art which may be introduced between the mass labels of this invention and their covalently attached biological molecule. Some of these linkers may be cleavable. Oligo- or poly-ethylene glycols or their derivatives may be used as linkers, such as those disclosed in Maskos, U. & Southern, E.M. Nucleic Acids Research 20: 1679-1684, 1992.
  • Succinic acid based linkers are also widely used, although these are less preferred for applications involving the labelling of oligonucleotides as they are generally base labile and are thus incompatible with the base mediated de-protection steps used in a number of oligonucleotide synthesisers.
  • Propargylic alcohol is a bifunctional linker that provides a linkage that is stable under the conditions of oligonucleotide synthesis and is a preferred linker for use with this invention in relation to oligonucleotide applications.
  • 6-aminohexanol is a useful bifunctional reagent to link appropriately functionalised molecules and is also a preferred linker.
  • cleavable linker groups may be used in conjunction with the compounds employed in this invention, such as photocleavable linkers.
  • Ortho-nitrobenzyl groups are known as photocleavable linkers, particularly 2-nitrobenzyl esters and 2-nitrobenzylamines, which cleave at the benzylamine bond.
  • photocleavable linkers see Lloyd-Williams et al., Tetrahedron 49, 11065-11133, 1993, which covers a variety of photocleavable and chemically cleavable linkers.
  • WO 00/02895 discloses the vinyl sulphone compounds as cleavable linkers, which are also applicable for use with this invention, particularly in applications involving the labelling of polypeptides, peptides and amino acids. The content of this application is incorporated by reference.
  • WO 00/02895 discloses the use of silicon compounds as linkers that are cleavable by base in the gas phase. These linkers are also applicable for use with this invention, particularly in applications involving the labelling of oligonucleotides. The content of this application is incorporated by reference.
  • the structure of the mass normalization moiety of the mass label used in the present invention is not particularly limited provided that it is suitable for ensuring that the mass label has a desired aggregate mass.
  • the mass normalization moiety preferably comprises a straight or branched C 1 -C 20 substituted or unsubstituted aliphatic group and/or one or more substituted or unsubstituted amino acids.
  • the mass normalization moiety comprises a C 1 -C 6 substituted or unsubstituted aliphatic group, more preferably a C 1 , C 2 , C 3 , C 4 , C 5 substituted or unsubstituted aliphatic group, still more preferably a C I , C 2 , or C 5 substituted or unsubstituted aliphatic group or a C 1 methyl substituted group.
  • the one or more substituted or unsubstituted amino acids may be any essential or non-essential naturally occurring amino acids or non-naturally occurring amino acids.
  • Preferred amino acids are alanine, ⁇ -alanine and glycine.
  • the substituents of the mass normalisation moiety are not particularly limited and may comprise any organic group and/or one or more atoms from any of groups IIIA, IVA, VA, VIA or VIIA of the Periodic Table, such as a B, Si, N, P, O, or S atom or a halogen atom (e.g. F, Cl, Br or I).
  • groups IIIA, IVA, VA, VIA or VIIA of the Periodic Table such as a B, Si, N, P, O, or S atom or a halogen atom (e.g. F, Cl, Br or I).
  • the organic group preferably comprises a hydrocarbon group.
  • the hydrocarbon group may comprise a straight chain, a branched chain or a cyclic group. Independently, the hydrocarbon group may comprise an aliphatic or an aromatic group. Also independently, the hydrocarbon group may comprise a saturated or unsaturated group.
  • the hydrocarbon when the hydrocarbon comprises an unsaturated group, it may comprise one or more alkene functionalities and/or one or more alkyne functionalities. When the hydrocarbon comprises a straight or branched chain group, it may comprise one or more primary, secondary and/or tertiary alkyl groups. When the hydrocarbon comprises a cyclic group it may comprise an aromatic ring, an aliphatic ring, a heterocyclic group, and/or fused ring derivatives of these groups.
  • the cyclic group may thus comprise a benzene, naphthalene, anthracene, indene, fluorene, pyridine, quinoline, thiophene, benzothiophene, furan, benzofuran, pyrrole, indole, imidazole, thiazole, and/or an oxazole group, as well as regioisomers of the above groups.
  • the number of carbon atoms in the hydrocarbon group is not especially limited, but preferably the hydrocarbon group comprises from 1-40 C atoms.
  • the hydrocarbon group may thus be a lower hydrocarbon (1-6 C atoms) or a higher hydrocarbon (7 C atoms or more, e.g. 7-40 C atoms).
  • the number of atoms in the ring of the cyclic group is not especially limited, but preferably the ring of the cyclic group comprises from 3-10 atoms, such as 3, 4, 5, 6 or 7 atoms.
  • the groups comprising heteroatoms described above, as well as any of the other groups defined above, may comprise one or more heteroatoms from any of groups IIIA, IVA, VA, VIA or VIIA of the Periodic Table, such as a B, Si, N, P, O, or S atom or a halogen atom (e.g. F, Cl, Br or I).
  • the substituent may comprise one or more of any of the common functional groups in organic chemistry, such as hydroxy groups, carboxylic acid groups, ester groups, ether groups, aldehyde groups, ketone groups, amine groups, amide groups, imine groups, thiol groups, thioether groups, sulphate groups, sulphonic acid groups, and phosphate groups etc.
  • the substituent may also comprise derivatives of these groups, such as carboxylic acid anhydrydes and carboxylic acid halides.
  • any substituent may comprise a combination of two or more of the substituents and/or functional groups defined above.
  • the reactive mass labels typically used in the present invention for labelling and detecting a biological molecule by mass spectroscopy comprise a reactive functionality for facilitating attachment of or for attaching the mass label to a biological molecule and a mass label as defined above.
  • the reactive functionality allows the mass label to be reacted covalently to an analyte, preferably an amino acid, peptide or polypeptide.
  • the reactive functionality may be attached to the mass labels via a linker which may or may not be cleavable.
  • the reactive functionality may be attached to the mass marker moiety of the mass label or the mass normalization moiety of the mass label.
  • a variety of reactive functionalities may be introduced into the mass labels used in this invention.
  • the structure of the reactive functionality is not particularly limited provided that it is capable of reacting with one or more reactive sites on the biological molecule to be labelled.
  • the reactive functionality is preferably a nucleophile or an electrophile.
  • this may be an N-hydroxysuccinimide ester.
  • An N-hydroxysuccinimide activated mass label could also be reacted with hydrazine to give a hydrazide reactive functionality, which can be used to label periodate oxidised sugar moieties, for example.
  • Amino-groups or thiols can be used as reactive functionalities in some applications.
  • Lysine can be used to couple mass labels to free carboxyl functionalities using a carbodiimide as a coupling reagent. Lysine can also be used as the starting point for the introduction of other reactive functionalities into the mass labels of this invention.
  • the thiol-reactive maleimide functionality can be introduced by reaction of the lysine epsilon amino group with maleic anhydride.
  • the cysteine thiol group can be used as the starting point for the synthesis of a variety of alkenyl sulphone compounds, which are useful protein labelling reagents that react with thiols and amines.
  • Compounds such as aminohexanoic acid can be used to provide a spacer between the mass modified mass marker moiety or mass normalization moiety and the reactive functionality.
  • Table 1 below lists some reactive functionalities that may be reacted with nucleophilic functionalities which are found in biomolecules to generate a covalent linkage between the two entities. Any of the functionalities listed below could be introduced into the compounds of this invention to permit the mass markers to be attached to a biological molecule of interest. A reactive functionality can be used to introduce a further linker groups with a further reactive functionality if that is desired. Table 1 is not intended to be exhaustive and the present invention is not limited to the use of only the listed functionalities.
  • each R 2 is independently H, a substituted or unsubstituted straight or branched C 1 -C 6 alkyl group, a substituted or unsubstituted aliphatic cyclic group, a substituted or unsubstituted aromatic group or a substituted or unsubstituted heterocyclic group.
  • the substituents of the reactive functionality are not particularly limited and may comprise any organic group and/or one or more atoms from any of groups IIIA, IVA, VA, VIA or VIIA of the Periodic Table, such as a B, Si, N, P, O, or S atom or a halogen atom (e.g. F, Cl, Br or I).
  • groups IIIA, IVA, VA, VIA or VIIA of the Periodic Table such as a B, Si, N, P, O, or S atom or a halogen atom (e.g. F, Cl, Br or I).
  • the organic group preferably comprises a hydrocarbon group.
  • the hydrocarbon group may comprise a straight chain, a branched chain or a cyclic group. Independently, the hydrocarbon group may comprise an aliphatic or an aromatic group. Also independently, the hydrocarbon group may comprise a saturated or unsaturated group.
  • the hydrocarbon when the hydrocarbon comprises an unsaturated group, it may comprise one or more alkene functionalities and/or one or more alkyne functionalities. When the hydrocarbon comprises a straight or branched chain group, it may comprise one or more primary, secondary and/or tertiary alkyl groups. When the hydrocarbon comprises a cyclic group it may comprise an aromatic ring, an aliphatic ring, a heterocyclic group, and/or fused ring derivatives of these groups.
  • the cyclic group may thus comprise a benzene, naphthalene, anthracene, indene, fluorene, pyridine, quinoline, thiophene, benzothiophene, furan, benzofuran, pyrrole, indole, imidazole, thiazole, and/or an oxazole group, as well as regioisomers of the above groups.
  • the number of carbon atoms in the hydrocarbon group is not especially limited, but preferably the hydrocarbon group comprises from 1-40 C atoms.
  • the hydrocarbon group may thus be a lower hydrocarbon (1-6 C atoms) or a higher hydrocarbon (7 C atoms or more, e.g. 7-40 C atoms).
  • the number of atoms in the ring of the cyclic group is not especially limited, but preferably the ring of the cyclic group comprises from 3-10 atoms, such as 3, 4, 5, 6 or 7 atoms.
  • the groups comprising heteroatoms described above, as well as any of the other groups defined above, may comprise one or more heteroatoms from any of groups IIIA, IVA, VA, VIA or VIIA of the Periodic Table, such as a B, Si, N, P, O, or S atom or a halogen atom (e.g. F, Cl, Br or I).
  • the substituent may comprise one or more of any of the common functional groups in organic chemistry, such as hydroxy groups, carboxylic acid groups, ester groups, ether groups, aldehyde groups, ketone groups, amine groups, amide groups, imine groups, thiol groups, thioether groups, sulphate groups, sulphonic acid groups, and phosphate groups etc.
  • the substituent may also comprise derivatives of these groups, such as carboxylic acid anhydrydes and carboxylic acid halides.
  • any substituent may comprise a combination of two or more of the substituents and/or functional groups defined above.
  • each label in the set has a common aggregate mass and each label in the set has a mass marker moiety of a unique mass.
  • each mass marker moiety in the set has a common basic structure and each mass normalisation moiety in the set has a common basic structure, and each mass label in the set comprises one or more mass adjuster moieties, the mass adjuster moieties being attached to or situated within the basic structure of the mass marker moiety and/or the basic structure of the mass normalisation moiety.
  • every mass marker moiety in the set comprises a different number of mass adjuster moieties and every mass label in the set has the same number of mass adjuster moieties.
  • skeleton comprises the mass marker moiety of the formula given above or the mass normalisation moiety as defined above.
  • the skeleton may additionally comprise a number of amino acids linked by amide bonds. Other units such as aryl ether units may also be present.
  • the skeleton or backbone may comprise substituents pendent from it, or atomic or isotopic replacements within it, without changing the common basic structure.
  • M is a mass normalisation moiety
  • X is a mass marker moiety
  • A is a mass adjuster moiety
  • L is a cleavable linker
  • y and z are integers of 0 or greater
  • y+z is an integer of 1 or greater.
  • M is a fragmentation resistant group
  • L is a linker that is susceptible to fragmentation on collision with another molecule or atom
  • X is preferably a pre-ionised, fragmentation resistant group.
  • M and X have the same basic structure or core structure, this structure being modified by the mass adjuster moieties.
  • the mass adjuster moiety ensures that the sum of the masses of M and X is the same for all mass labels in a set, but ensures that each X has a distinct (unique) mass.
  • the mass adjuster moiety (A) is preferably selected from:
  • the mass adjuster moiety is selected from a halogen atom substituent, a methyl group substituent, and 2 H, 15 N, 18 O, or 13 C isotopic substituents.
  • each mass label in the set of mass labels as defined above has the following structure:
  • X is the mass marker moiety
  • L is the cleavable linker
  • M is the mass normalisation moiety
  • * is an isotopic mass adjuster moiety
  • n and m are integers of 0 or greater such that each label in the set comprises a mass marker moiety having a unique mass and each label in the set has a common aggregate mass.
  • X comprises the following group:
  • R 1 , Z, X and y are as defined above and each label in the set comprises 0, 1 or more * such that each label in the set comprises a mass marker moiety having a unique mass and each label in the set has a common aggregate mass.
  • the reactive mass labels of the present invention comprise the following reactive functionality group:
  • R 2 is as defined above and the set comprises 0, 1 or more * such that each label in the set comprises a mass marker moiety having a unique mass and each label in the set has a common aggregate mass.
  • the isotopic species * is situated within the mass marker moiety and/or the linker and/or the mass adjuster moiety, rather than on any reactive moiety that is present to facilitate attaching the label to an analyte.
  • the number of isotopic substituents is not especially limited and can be determined depending on the number of labels in the set.
  • the number of * species is from 0-20, more preferably from 0-15 and most preferably from 1-10, e.g. 1, 2, 3, 4, 5, 6, 7 or 8.
  • the number of species * is 1, whilst in a set of 5 labels, it is preferred that the number is 4, whilst in a set of 6 labels it is preferred that the number is 5.
  • the number may be varied depending upon the chemical structure of the label.
  • isotopic variants of S may also be employed as mass adjuster moieties, if the labels contain one or more sulphur atoms.
  • the set of reactive mass labels comprises two mass labels having the following structures:
  • the set of reactive mass labels comprises the set comprises five mass labels having the following structures:
  • the set of reactive mass labels comprises six mass labels I-VI having the following structures, or stereoisomers of these structures:
  • the method according to the present invention may comprise a further step of separating the components of the samples prior to step (a).
  • the method may also comprise a step of digesting each sample with at least one enzyme to digest components of the samples prior to step (a).
  • the enzyme digestion step may also occur after step (a) but before step (b).
  • the mass labels used in the method further comprise an affinity capture ligand.
  • the affinity capture ligand of the mass label binds to a counter-ligand so as to separate the isobarically labeled analytes from the unlabelled analytes after step (a) but before step (b).
  • Affinity capture ligands are ligands which have highly specific binding partners. These binding partners allow molecules tagged with the ligand to be selectively captured by the binding partner.
  • a solid support is derivitised with the binding partner so that affinity ligand tagged molecules can be selectively captured onto the solid phase support.
  • a preferred affinity capture ligand is biotin, which can be introduced into the mass labels of this invention by standard methods known in the art. In particular a lysine residue may be incorporated after the mass marker moiety or mass normalization moiety through which an amine-reactive biotin can be linked to the mass labels (see for example Geahlen R. L.
  • affinity capture ligands include digoxigenin, fluorescein, nitrophenyl moieties and a number of peptide epitopes, such as the c-myc epitope, for which selective monoclonal antibodies exist as counter-ligands.
  • Metal ion binding ligands such as hexahistidine, which readily binds Ni 2+ ions, are also applicable.
  • Chromatographic resins which present iminodiacetic acid chelated Ni 2+ ions are commercially available, for example. These immobilised nickel columns may be used to capture mass labels.
  • an affinity capture functionality may be selectively reactive with an appropriately derivatised solid phase support. Boronic acid, for example, is known to selectively react with vicinal cis-diols and chemically similar ligands, such as salicylhydroxamic acid.
  • the method according to the invention may further include the step of separating the isobarically labeled analytes electrophoretically or chromatographically after step (a) but before step (b).
  • strong cation exchange chromatography is used.
  • test sample refers to any specimen in which an analyte may be present.
  • the test sample may comprise only one analyte.
  • the test sample may comprise a plurality of different analytes.
  • a calibration sample is provided for each different analyte.
  • the test sample may be from a natural source or may be produced synthetically.
  • An example of a synthetic sample is a mixture of recombinant proteins.
  • the test sample is a complex mixture, for example a sample from a plant or an animal. In a preferred embodiment the sample is from a human.
  • test samples assayed in the present invention include: mammalian tissue, fluids such as blood, plasma, serum cerebrospinal fluid, synovial fluid, ocular fluid, urine, tears and tear duct exudate, lung aspirates including bronchoalveolar lavage fluid, breast milk, nipple aspirate, semen, lavage fluids, cell extracts, cell lines and sub-cellular organelles, tissues such as solid organ tissues, cell culture supernatants or preparations derived from mammals, fish, birds, insects, annelids, protozoa and bacteria, tissue culture extracts, plant tissues, plant fluids, plant cell culture extracts, bacteria, viruses, fungi, fermentation broths, foodstuffs, pharmaceuticals and any intermediary products.
  • mammalian tissue such as blood, plasma, serum cerebrospinal fluid, synovial fluid, ocular fluid, urine, tears and tear duct exudate
  • lung aspirates including bronchoalveolar lavage fluid, breast milk, nipple aspirate
  • test sample is blood plasma.
  • test sample is depleted blood plasma. This is blood plasma which has been purified to remove the most abundant plasma proteins, such as albumin, so as to reduce the protein load in the sample, hence reducing the number of analytes in the sample.
  • calibration sample refers to a sample which comprises at least two different aliquots of the analyte.
  • the different aliquots each have a known quantity of the analyte.
  • known quantity means that the absolute quantity, or a qualitative quantity of the analyte in each aliquot of the calibration sample is known.
  • a qualitative quantity in the present context means a quantity which is not known absolutely, but may be a range of quantities that are expected in a subject having a particular state, for example a subject in a healthy or diseased state, or some other expected range depending on the type of test sample under investigation.
  • Each aliquot is “different” since it contains a different quantity of the analyte. Typically this is achieved by taking different volumes from a standard sample, especially for qualitative quantities where taking different volumes will ensure that different quantities are present in each aliquot in a desired ratio, without needing to know the absolute quantities.
  • each aliquot is prepared separately and is not taken from the same sample. In one embodiment, each different aliquot has the same volume, but comprises a different quantity of the analyte.
  • the calibration sample may be a natural sample such as a body fluid or a tissue extract or may be synthetic, as for the sample to be assayed.
  • the calibration sample may comprise a recombinantly expressed protein, synthetically manufactured peptide or oligonucleotide.
  • European patent application EP 1736480 discloses methods of producing multiple reference peptides as a concatenated recombinant protein for use in multiple reaction monitoring experiments in a mariner analogous to the AQUA methodology. Such methods of production may be combined with isobaric mass labels to provide the calibration samples according to any of the various aspects of this invention.
  • the calibration sample may be a standardised form of the sample to be assayed.
  • the calibration sample may comprise all of the components of the sample to be assayed but in particular quantities.
  • the calibration sample may comprise a standardised preparation of mammalian tissue, fluids such as blood, plasma, serum cerebrospinal fluid, synovial fluid, ocular fluid, urine, tears and tear duct exudate, lung aspirates including bronchoalveolar lavage fluid, breast milk, nipple aspirate, semen, lavage fluids, cell extracts, cell lines and sub-cellular organelles, tissues such as solid organ tissues, cell culture supernatants or preparations derived from mammals, fish, birds, insects, annelids, protozoa and bacteria, tissue culture extracts, plant tissues, plant fluids, plant cell culture extracts, bacteria, viruses, fungi, fermentation broths, foodstuffs, pharmaceuticals and any intermediary products. If the analytes of interest are proteins, since all proteins in the calibration sample are labelled, the
  • the calibration sample may comprise only analytes to be assayed in the sample, and not any other components of the sample.
  • the calibration sample comprising one or more analytes may be produced and isobarically labelled exogenously and added to the complex mixture containing the analyte.
  • a calibration sample can be prepared which comprises different aliquots of the recombinant form of the protein.
  • the quantity of analyte in each aliquot in the calibration sample is a known absolute quantity. This allows for the absolute quantity of an analyte in a test sample to be determined in step (b).
  • the absolute quantity of an analyte in each aliquot in the calibration sample is not known.
  • the quantity of analyte in each aliquot in the calibration sample is a known qualitative quantity.
  • the calibrating step comprises calibrating the quantity of the analyte in the test sample against the qualitative and determined quantities of the analytes in the aliquots of the calibration sample.
  • the qualitative quantity is an expected range of quantities of analyte in a subject having a particular state, such as a healthy or diseased state. Assays which provide such calibration samples for relative quantitation have wide range of applications including biomarker discovery, industrial microbiology, pharmaceutical and food manufacture and the diagnosis and management of human and veterinary disease
  • Relative quantitation experiments are often useful when analysing complex biological samples such as blood plasma.
  • a large amount of entire human blood plasma is split into several (i.e, four) aliquots and individually labelled with different isobaric mass labels.
  • 6TMT-128, 6TMT-129, 6TMT-130, 6TMT-131 would be used for labelling. All individual samples of a blood plasma study are labelled with one further different version of this isobaric mass tag, i.e. 6TMT-126.
  • the aliquots of blood plasma can now be used to generate a calibration curve, for instance by mixing the 4 aliquots in a 0.5 to 1 to 2 to 5 ⁇ L ratio to produce a calibration sample, and then adding 1 ⁇ l of the study sample.
  • the calibration sample comprising four differentially labelled aliquots
  • virtually all MS/MS experiments performed with this material will result in groups of five reporter-ions four from the calibration sample and one from the sample.
  • the entire proteome can be used in a 4-point calibration curve. If all plasma samples of the study are spiked with the identical amount of the calibration sample, relative quantification across all study samples becomes possible. Since the calibration sample can be used by multiple laboratories, cross-study and cross-laboratory comparisons are possible.
  • the % change in quantity can be calculated from the calibration curve.
  • the ratio and width of the calibration curve can be adjusted.
  • the quantity of analyte in each different aliquot of the calibration sample is selected to reflect the known or suspected variation of the analyte in the test sample.
  • aliquots are provided which comprise the analyte in quantities which correspond to the upper and lower limits, and optionally intermediate points within a range of the known or suspected quantities of the analyte found in test samples of healthy or diseased subjects.
  • each analyte is quantified independently of all other analytes in the sample it is conceivable to prepare multiple sets of calibration samples each at widely different concentrations to all other calibration samples, so enhancing the dynamic range of the experiment. It is also possible to prepare a number of reference biomolecules for each analyte wherein each biomolecule is provided in a range of overlapping quantities thereby extending the total range of the standard curve for a given analyte. As an example a number of different tryptic peptides from a target protein may be selected for use as reference standards based on their performance in a tandem mass spectrometer.
  • the reference peptides may be selected on the basis of the ion intensity of the ion corresponding to the peptide in a mass spectrum or on the basis of the signal-to-noise ratio in the area of the spectrum in which the ion corresponding to the peptide appears. Alternatively the reference peptides may be selected so as to avoid peptides which have isobaric species. The selection of proteotypic peptides, i.e. peptides which are only present in a particular protein is particularly favoured.
  • each standard peptide is independently labelled with up to five different members of a six-plex set of isobaric mass tags these may be mixed in different ratios to provide a five-point standard curve.
  • the same isobaric mass labels may be used to label second, third, fourth or more standard peptides each of which may be mixed in different ratios covering a range of concentrations different to that covered by each of the other reference peptides for the same analyte.
  • a different calibration curve is produced for each peptide derived from the target protein, each calibration curve covering a different range of concentrations.
  • the concentration of each peptide is then determined from their respective calibration curve, and this can be related back to the concentration of the target protein.
  • the quantity of the peptide in the test sample may fall in the middle of the calibration curve, providing an accurate determination of its actual quantity in the sample.
  • the quantity of the peptide in the test sample may fall outside the range of the calibration curve.
  • the calibration sample may comprise a normal quantity of an analyte.
  • the quantity of the analyte in the calibration sample may indicate that a plant, animal, or preferably a human is healthy.
  • the calibration sample may comprise an analyte in a quantity that indicates the presence and/or stage of a particular disease.
  • the calibration sample comprises an analyte in a quantity that indicates the efficacy and/or toxicity of a therapy. Standard panels of known markers of a particular trait such as presence and/or stage of disease, response to therapy, and/or toxicity are prepared.
  • Calibration samples comprising body fluids or tissue extracts labelled with an isobaric mass tag could be prepared from patients with well characterised disease including but not limited to tumours, neurodegeneration, cardiovascular, renal, hepatic, respiratory, metabolic, inflammatory, and infectious diseases.
  • Known amounts of such samples are added to multiple test samples in such a manner that for a series of analyses ion intensities in the MS/MS scan can be normalised based on the ion intensity of the common calibration sample, thereby providing more accurate comparisons between the separate analyses, reducing the analytical variability of the study.
  • each reference peptide is labelled with one of three isobaric mass tags from a set of such isobaric mass tags wherein all tags in the set have substantially the same aggregate mass as determined by mass spectrometry and wherein each tag in the set releases a mass reporter ion of unique mass on collision induced dissociation in a mass spectrometer.
  • Each unique reference peptide-mass tag molecule is then added to a carrier solution such as a MS-compatible buffer at a known concentration such that the concentration of the three differentially labelled aliquots of the same reference peptide are different, and that the differences span the normal biological concentrations of the parent protein in patients with cardiac disease.
  • the resultant reference peptide panel is added at a defined volumetric ratio with a test sample that has been labelled with a fourth isobaric mass tag from the same set of isobaric mass tags used to label the reference peptides.
  • the spiked sample is then subjected to tandem mass spectrometry wherein the survey scan is performed in a directed manner to only identify those precursor ions of characteristic retention time and mass correlating to each of the isobarically labelled reference peptides.
  • the MS/MS scan will contain reporter ions derived from the high, medium and low concentration reference peptides and the test sample.
  • a simple standard curve is easily constructed from the reference peptide reporter ion intensities and the fourth reporter ion from the same peptide in the test sample can be read against the calibration curve.
  • the absolute concentration of multiple biologically relevant proteins can be determined in a single MS/MS experiment.
  • the skilled artisan will be aware that the number of different proteins for which reference peptides are prepared need not be particularly limited and will be in the range of 1-100 and most preferably 1-50. Similarly the number of representative peptides may be in the range of 1-20, preferably 1-10, more preferably 1-5 and most preferably 1-3. It would be understood by the skilled artisan that the example described above is a general examplar and the principles described therein may be applied to known markers of any disease and applied for disease diagnosis, monitoring of disease progression or monitoring the response of a patient to treatment.
  • a further application is in the use of these calibration samples in time course experiments.
  • the “Status” of a sample with respect to time course can be established if the (4) different aliquots are from 4 different time points, such as time zero, 1 hour, 8 hours, and 24 hours into an experiment (drug challenge in mice and man, induction of fermentation in E. coli and yeast), also on a longer time scale of weeks and months for development or treatment response of chronic diseases.
  • one of the aliquots of the calibration sample comprises an analyte in a quantity which serves as a trigger during an MS scan or during non-scanning MS/MS to initiate an MS/MS scan.
  • Non-scanning MS/MS is when you do not select for any particular ion with a given m/z ratio in a mass analyser in a mass spectrometer, but instead essentially all of the analytes are fragmented to produce an unspecific fragment spectrum. Typically, this involves allowing all ions to pass from a first mass analyser into a collision cell, where CID occurs on all of the analytes in the sample instead of a particular selected ion as in conventional MS/MS.
  • the reporter ion from the trigger can be used as an indicator that an analyte of interest is right now entering the mass spectrometer.
  • the presence of a reporter ion from the trigger indicates that an analyte of interest is eluting from an LC column during LC-MS. This would “trigger” the execution of a pre-defined MS/MS experiment.
  • This trigger may not necessarily be an analyte labelled with an isobaric mass label.
  • the trigger may be any other labelled analyte which co-elutes, or substantially co-elutes with the labelled analyte of interest during LC-MS.
  • the label of the trigger analyte may have a different mass to that of the isobaric mass labels of the calibration sample.
  • the calibration sample comprises aliquots of an analyte differentially labelled with isobaric mass labels, and further comprises an aliquot of the analyte which is labelled with a chemically identical but isotopically distinct mass label, preferably with a mass difference of 5 Da from that of the isobaric mass labels.
  • the isotopically distinct mass label could then serve as the “trigger”.
  • each analyte present in the calibration sample bearing the isotopically distinct and isobaric labels will appear as a pair of peaks separated by the mass difference between the isobaric and isotopically distinct labels and wherein the analyte bearing the isotopically distinct label is present in a readily detectable amount.
  • the mass spectrometer is programmed to perform a dedicated MS/MS experiment on the isobarically labelled analyte in such pairs, thereby triggering the quantitative analysis of the analytes of interest.
  • the isotopically distinct mass label trigger comprises no isotopic substituents
  • the isobaric mass labels comprise a plurality of isotopic substituents, preferably 2 H, 15 N, 18 O, or 13 C isotopic substituents. This provides a mass difference between the analytes of the calibration sample labelled with isobaric mass labels and the analyte labelled with the trigger label. Since the trigger label comprises no isotopic substituents, this label can be used in large quantities if required without the need for costly isotope labelling.
  • the present invention also provides a method for increasing the detectability of low abundance analytes in a sample.
  • a recombinant reference protein may be expressed and then labelled with an isobaric mass tag.
  • a test sample is then labelled with a second member of the same set of isobaric mass labels and a large amount of the isobarically labelled recombinant reference protein is added to the test sample at such a concentration as to be readily detectable by any chosen method which might include one- or two-dimensional gel electrophoresis, free-flow electrophoresis, capillary electrophoresis, off-gel isoelectric focussing and LC-MS/MS, LC-MS n and/or LC-TOF/TOF.
  • a MS/MS scan or TOF/TOF analysis is performed and the reporter masses of the reference material and test sample are quantified.
  • a non-isobaric label can also be used to label the trigger analyte in this embodiment if it can be detected together with the labelled analytes of interest, for example if the trigger analyte and isobarically labelled analytes appear at the same spot on a gel or co-elute during LC-MS.
  • BSA bovine serum albumin
  • the tryptic digest was split into four aliquots and each aliquot was labelled with a different member of the sixplex TMT labels of WO 2007/012849 whereby the first aliquot was labelled with the TMT label whose mass marker moiety has a mass of 128 Da, the second aliquot with the TMT label whose mass marker moiety has a mass of 129 Da, the third aliquot with the TMT label whose mass marker moiety has a mass of 130 Da and the final aliquot with the TMT label whose mass marker moiety has a mass of 131 Da. Labelling was performed by adding each respective TMT label reagent stock solutions (60 mM in acetonitrile) to the respective sample to give a final concentration of 15 mM TMT reagent.
  • the accuracy of quantitation of the BSA standard prepared in Example 1 was determined by analyzing a series of solutions of known BSA concentration into which the BSA standard solution was spiked.
  • FIG. 2 shows an MS/MS profile for BSA tryptic peptide AEFVEVTK.
  • Upper panel shows the full MS/MS spectrum.
  • Lower panel shows zoom of isobaric mass marker moiety region and the different intensities reflecting different abundance of the same peptide in the study sample (126) and reference material (128, 129, 130 & 131).
  • MS/MS spectra are then analysed by SequestTM and matched to an actual release of IPI database.
  • Protein ID accession number plus partial sequence as extracted from MS/MS scan
  • retention times as well as reporter ion intensities of all reporters (126, 128, 129, 130 & 131 Da) are exported into an excel spreadsheet.
  • peptides with low intensity reporters are excluded if their analytical precision and quality are questionable, as well as peptides where reporters are outside of defined intensity thresholds.
  • the standard curve for this experiment was calculated by adding all the TMT mass marker moiety intensities of the BSA-derived tryptic peptides (128, 129, 130 & 131 Da respectively) for each reference amount of BSA and plotting the summed ion intensity against absolute BSA amount injected.
  • the standard curve is shown in FIG. 3 .
  • To calculate the amount of BSA in the analytical sample the ion intensities of all of the 126 Da TMT mass marker moiety intensities were added and this value read against the standard curve. This gave a calculated BSA amount injected of 0.892 ⁇ g (one outlier peptide discarded for analysis). If data for individual peptides were used the calculated range was 0.751 to 1.016 ⁇ g BSA.
  • the analyte of interest to be quantified by using the invention was the protein clusterin.
  • One clusterin peptide with the amino acid sequence depicted below was used as a reference:
  • This peptide has a molecular weight of 2313.17 Da (monoisotopic) or 2314.53 Da (average).
  • This peptide corresponds to residues 386-408 within the SwissProt entry (CLUS_HUMAN), and is a part of the a chain of matured clusterin that has a molecular weight of 25878 Da.
  • the peptide is estimated to contain 3 ⁇ TFA counter ions, causing an increase of the molecular weight to 2655 g/mol when generating the peptide stock.
  • a 1 ⁇ g/ ⁇ L peptide stock was obtained from 1.66 mg peptide. 4 portions of 200 ⁇ L each were labelled with TMT6-128, TMT6-129, TMT6-130 and TMT6-131 respectively. The peptides were treated with NH 2 OH to reverse possible Tyrosine, Serine and Threonine labelling. The differentially labelled peptide samples were then mixed in a 1:2:4:8 ratio.
  • FIG. 6 shows a schematic of the methodology used. Initial analysis by LC-MS/MS showed that partial overlabelling was not completely reversed, and therefore a second treatment was necessary. The calibration sample was diluted by a factor of 528 prior to mixing with the TMT6-128 labelled plasma samples.
  • each plasma sample was diluted with 198.33 ⁇ L buffer (100 mM TEAB, 0.1% SDS, pH 8.5), providing 142-200 ⁇ g protein in total (0.71-1.004 ⁇ L protein concentration).
  • Each plasma sample was then labeled with TMT6-126, and an NH 2 OH treatment was carried out according to the optimised conditions. 4 ⁇ L of diluted calibration sample was then added to 10% of each sample. The sample was then purified by reverse phase as well as strong cation exchange chromatography.
  • FIG. 7 shows the mass spectrum from the retention profile of the labelled peptide from clusterin.
  • Targeted MS/MS acquisition was then carried out using include lists that contained the m/z of the TMT-labelled peptide from clusterin. Optimisation of collision energy parameters was performed to obtain increased mass marker group ion intensities.
  • FIG. 8 shows the MS/MS spectrum of the labelled peptide from clusterin. As inset is shown the region of the MS/MS spectrum which shows the mass marker ions.
  • Human Plasma was purchased from Dade Behring (Standard Plasma). The plasma was spiked with two proteins:
  • Type I-AS From Bovine Pancreas (Sigma, R-5503), MW 13.7 kDa; pI 9.6; 85% purity. 1.8 mg were dissolved in 170 ⁇ L water; 10 ⁇ L of this solution was added to 1 ml Plasma prior to depletion of high abundant proteins.
  • Trypsin Inhibitor, Type I-S From Soybean (Sigma, T-9003); MW 20.1 kDa; pI 4.5; 90% Protein content; ⁇ -chain MW 20090 Da; ⁇ -Chain MW 20036 Da; Chain MW 20163 Da. 8.8 mg were dissolved in 196 ⁇ L water; 10 ⁇ L of this solution was added to 1 ml Plasma prior to depletion of high abundant proteins.
  • the Protein treatment was performed following standard protocols. Protein was diluted to a 1 g/L protein solution pH 7.5 in 100 mM Borate buffer and 0.1% Sodium dodecylsulfate. Reduction of the cysteins with 1 mM TCEP was performed for 30 min at room temperature. The cysteins were alkylated with Iodoacetamide for one hour at room temperature. 440 mg Trypsin were added and incubated for 18-24 hours at 37° C.
  • the SCX gradient was formed with solvents C (Water 75% Acetonitrile 25%+5 mM KH 2 PO 4 , pH 3) and D (Water 75% Acetonitrile 25%+5 mM KH 2 PO 4 , pH 3+500 mM KCl, pH 3) from 0 to 50% in 30 minutes. 24 SCX fractions were collected from this separation step. Each fraction was subsequently subjected to reverse-phase separation.
  • the second separation system was a reversed phase chromatography on a Waters nanoAQUITY HPLC System. Due to the decoupling of the chromatography and the MS measurements in the MALDI workflow the HPLC conditions could be optimized to get a high peak capacity.
  • Column oven temperature 60° C. 5 ⁇ L of each SCX fraction were injected directly without any precolumn on the HPLC column.
  • the separation column of the nanoACQUITY HPLC System is joined to the inlet of a Dionex Probot spotter to fractionate the peptides in MALDI preparations on a Microtiter format MALDI sample target for the 4800 T of/T of MALDI instrument. On a MALDI target 1920 individual fractions can be collected. Four RP chromatograms each with 480 spots were prepared per MALDI target. The spotting starts at retention time 50 minutes and ends at retention time 210 min with a spotting duration of 20 seconds per spot.
  • each MALDI preparation has a volume of about 330 mL.
  • the spots were run in two modes on the 4800 T of/T of instrument. In a first run in Reflector mode conventional MS spectra were recorded. 1,000 MALDI Shots were summed up for each individual MS Spectrum. The spectra were calibrated internally with the matrix trimer signal at m/z 568.138 Th.
  • the interpretation tool of the “4000 Series Explorer” instrument software generated a precursor list of MS/MS experiments using a LC MALDI strategy that includes the calculation of elution profiles for the peptide peaks (fraction to fraction mass tolerance 100 ppm, exclusion of precursors within 200 resolution). Up to five precursors were allowed per spot to be selected for subsequent MS/MS analysis. The MS/MS acquisition was on the strongest precursors first. 1,000 laser shots were acquired per spectrum. The MS/MS spectra were calibrated internally with the theoretical mass value of the TMT J -131 fragment ion 131.1387 Th.
  • the Quantitation of reporter peaks at the masses 128, 129, 130 and 131 Da was performed via the Extraction of the Peak areas out of the GPS Oracle data base. After peak area calculation, regression analysis was performed in order to check for quality of the calibration curve (1:2:4:8 ratio). Each peptide MS/MS experiment was checked by analysing the reporter peaks for the fit to a straight line. A linear regression was performed for every MS/MS spectrum.
  • FIGS. 10 , 11 and 12 show representative examples of an MS/MS spectrum.
  • the sequencing b- and y-ions are seen.
  • a zoom is displayed demonstrating the reporter region with the reporters on 128, 129, 130 and 131 m/z with their 1:2:4:8 ratios.
  • MS/MS spectra In total, about 12,000 MS/MS spectra were generated which showed reporter ion intensities fulfilling the intensity criteria for quantification.
  • the MALDI TofT of MS/MS spectra show the TMT tag fragment ion in good intensity to allow for quantification purposes.
  • the y- and b-ion series in the MS/MS spectra of the peptides were used for peptide ID.
  • the data base search with conservative thresholds gave 141 human protein identifications in the IPI Human data base. Both spiked proteins were found using the Swissprot database and species related filtering. Among the identified human proteins there was for example Clusterin found with 18 MS/MS spectra and 25% Sequence coverage. Regression analysis shows that more than half of the MS/MS spectra have a R 2 value better than 0.99. 90% have a R 2 value better than 0.94.
  • IPI00029739 Gene_Symbol CFH Isoform 1 of Complement factor H precursor 16.
  • IPI00218192 Gene_Symbol ITIH4 Isoform 2 of Inter-alpha-trypsin inhibitor heavy chain H4 precursor 17.
  • IPI00550991 Gene_Symbol SERPINA3 Alpha-1-antichymotrypsin precursor 18.
  • IPI00019591 Gene_Symbol CFB Isoform 1 of Complement factor B precursor (Fragment) 19.
  • IPI00294193 Gene_Symbol ITIH4; TMEM110 Isoform 1 of Inter-alpha- trypsin inhibitor heavy chain H4 precursor 20.
  • IPI00026314 Gene_Symbol GSN Isoform 1 of Gelsolin precursor 21.
  • IPI00022895 Gene_Symbol A1BG Alpha-1B-glycoprotein precursor 22.
  • IPI00793618 Gene_Symbol C3 13 kDa protein 23.
  • IPI00022488 Gene_Symbol HPX Hemopexin precursor 24.
  • IPI00641737 Gene_Symbol HP Haptoglobin precursor 25.
  • IPI00022391 Gene_Symbol APCS Serum amyloid P-component precursor 26.
  • IPI00019580 Gene_Symbol PLG Plasminogen precursor 27.
  • IPI00298828 Gene_Symbol APOH Beta-2-glycoprotein 1 precursor 28.
  • IPI00019568 Gene_Symbol F2 Prothrombin precursor (Fragment) 29.
  • IPI00218732 Gene_Symbol PON1 Serum paraoxonase/arylesterase 1 30.
  • IPI00022431 Gene_Symbol AHSG Alpha-2-HS-glycoprotein precursor 31.
  • IPI00032291 Gene_Symbol C5 Complement C5 precursor 32.
  • IPI00829768 Gene_Symbol IGHM IGHM protein 33.
  • IPI00477090 Gene_Symbol IGHM IGHM protein 34.
  • IPI00844156 Gene_Symbol SERPINC1 SERPINC1 protein 35.
  • IPI00032179 Gene_Symbol SERPINC1 Antithrombin III variant 36.
  • IPI00304273 Gene_Symbol APOA4 Apolipoprotein A-IV precursor 37.
  • IPI00022426 Gene_Symbol AMBP AMBP protein precursor 38.
  • IPI00298971 Gene_Symbol VTN Vitronectin precursor 39.
  • IPI00025426 Gene_Symbol PZP Pregnancy zone protein precursor 40.
  • IPI00022371 Gene_Symbol HRG Histidine-rich glycoprotein precursor 41.
  • IPI00022394 Gene_Symbol C1QC Complement C1q subcomponent subunit C precursor 42.
  • IPI00477597 Gene_Symbol HPR Isoform 1 of Haptoglobin-related protein precursor 43.
  • IPI00021857 Gene_Symbol APOC3 Apolipoprotein C-III precursor 44.
  • IPI00555812 Gene_Symbol GC Vitamin D-binding protein precursor 45.
  • IPI00007221 Gene_Symbol SERPINA5 Plasma serine protease inhibitor precursor 59.
  • IPI00385264 Gene_Symbol -Ig mu heavy chain disease protein 60.
  • IPI00006662 Gene_Symbol APOD Apolipoprotein D precursor 61.
  • IPI00303963 Gene_Symbol C2 Complement C2 precursor (Fragment) 62.
  • IPI00291867 Gene_Symbol CFI Complement factor I precursor 63.
  • IPI00022395 Gene_Symbol C9 Complement component C9 precursor 64.
  • IPI00430820 Gene_Symbol IGKV1-5 IGKV1-5 protein 65.
  • IPI00009920 Gene_Symbol C6 Complement component C6 precursor 66.
  • IPI00020996 Gene_Symbol IGFALS Insulin-like growth factor-binding protein complex acid labile chain precursor 67.
  • IPI00032220 Gene_Symbol AGT Angiotensinogen precursor 68.
  • IPI00168728 Gene_Symbol IGHM FLJ00385 protein (Fragment) 69.
  • IPI00019581 Gene_Symbol F12 Coagulation factor XII precursor 70.
  • IPI00020986 Gene_Symbol LUM Lumican precursor 71.
  • IPI00294395 Gene_Symbol C8B Complement component C8 beta chain precursor 72.
  • IPI00654888 Gene_Symbol KLKB1 Uncharacterized protein KLKB1 73.
  • IPI00299503 Gene_Symbol GPLD1 Isoform 1 of Phosphatidylinositol- glycan-specific phospholipase D precursor 74.
  • IPI00022429 Gene_Symbol ORM1 Alpha-1-acid glycoprotein 1 precursor 75.
  • IPI00296608 Gene_Symbol C7 Complement component C7 precursor 76.
  • IPI00009793 Gene_Symbol C1RL Complement C1r-like protein 77.
  • IPI00019943 Gene_Symbol AFM Afamin precursor 78.
  • IPI00022417 Gene_Symbol LRG1 Leucine-rich alpha-2-glycoprotein precursor 79.
  • IPI00296165 Gene_Symbol C1R; C17orf13; LOC442122; ACYP1; RP11- 114H20.1 Complement C1r subcomponent precursor 80.
  • IPI00020091 Gene_Symbol ORM2 Alpha-1-acid glycoprotein 2 precursor 81.
  • IPI00328609 Gene_Symbol SERPINA4 Kallistatin precursor 82.
  • IPI00011264 Gene_Symbol CFHR1 Complement factor H-related protein 1 precursor 83.
  • IPI00179330 Gene_Symbol UBB; UBC; RPS27A ubiquitin and ribosomal protein S27a precursor 84.
  • IPI00011252 Gene_Symbol C8A Complement component C8 alpha chain precursor 85.
  • IPI00019399 Gene_Symbol SAA4 Serum amyloid A-4 protein precursor 86.
  • IPI00163207 Gene_Symbol PGLYRP2 Isoform 1 of N-acetylmuramoyl-L- alanine amidase precursor 87.
  • IPI00022420 Gene_Symbol RBP4 Plasma retinol-binding protein precursor 88.
  • IPI00791350 Gene_Symbol CLEC3B 11 kDa protein 89.
  • IPI00218413 Gene_Symbol BTD biotinidase precursor 90.
  • IPI00294004 Gene_Symbol PROS1 Vitamin K-dependent protein S precursor 91.
  • IPI00009028 Gene_Symbol CLEC3B Tetranectin precursor 92.
  • IPI00382480 Gene_Symbol -Ig heavy chain V-III region BRO 93.
  • IPI00296176 Gene_Symbol F9 Coagulation factor IX precursor 94.
  • IPI00477992 Gene_Symbol C1QB complement component 1, q subcomponent, B chain precursor 95.
  • IPI00154742 Gene_Symbol IGL@ IGL@ protein 96.
  • IPI00292946 Gene_Symbol SERPINA7 Thyroxine-binding globulin precursor 97.
  • IPI00382938 Gene_Symbol IGLV4-3 IGLV4-3 protein 98.
  • IPI00299778 Gene_Symbol PON3 Serum paraoxonase/lactonase 3 99.
  • IPI00410714 Gene_Symbol HBA2; HBA1 Hemoglobin subunit alpha 100.
  • IPI00296534 Gene_Symbol FBLN1 Isoform D of Fibulin-1 precursor 101.
  • IPI00027235 Gene_Symbol ATRN Isoform 1 of Attractin precursor 102.
  • IPI00216882 Gene_Symbol MASP1 mannan-binding lectin serine protease 1 isoform 3 110.
  • IPI00387115 Gene_Symbol -Ig kappa chain V-III region SIE 111.
  • IPI00003590 Gene_Symbol QSOX1 Isoform 1 of Sulfhydryl oxidase 1 precursor 112.
  • IPI00022432 Gene_Symbol TTR Transthyretin precursor 113.
  • IPI00029061 Gene_Symbol SEPP1 Selenoprotein P precursor 114.
  • IPI00028413 Gene_Symbol ITIH3 Inter-alpha-trypsin inhibitor heavy chain H3 precursor 115.
  • IPI00479116 Gene_Symbol CPN2 Carboxypeptidase N subunit 2 precursor 116.
  • IPI00178926 Gene_Symbol IGJ immunoglobulin J chain 117.
  • IPI00166729 Gene_Symbol AZGP1 alpha-2-glycoprotein 1, zinc 118.
  • IPI00445707 Gene_Symbol MAEA CDNA FLJ43512 fis, clone PERIC2004028, moderately similar to Mus musculus erythroblast macrophage protein EMP mRNA 119.
  • IPI00329775 Gene_Symbol CPB2 Isoform 1 of Carboxypeptidase B2 precursor 120.
  • IPI00008603 Gene_Symbol ACTA2 Actin, aortic smooth muscle 121.
  • IPI00384938 Gene_Symbol IGHG1 Putative uncharacterized protein DKFZp686N02209 122.
  • IPI00784822 Gene_Symbol IGHV4-31 IGHV4-31 protein 123.
  • IPI00027482 Gene_Symbol SERPINA6 Corticosteroid-binding globulin precursor 124.
  • 1PI00795068 Gene_Symbol RRBP1 Ribosome binding protein 1 homolog 180 kDa 125.
  • IPI00025204 Gene_Symbol CD5L CD5 antigen-like precursor 126.
  • IPI00003351 Gene_Symbol ECM1 Extracellular matrix protein 1 precursor 127.
  • IPI00163446 Gene_Symbol IGHD IGHD protein 128.
  • IPI000I0252 Gene_Symbol TRIM33 Isoform Alpha of E3 ubiquitin- protein ligase TRIM33 129.
  • IPI00041065 Gene_Symbol HABP2 Hyaluronan-binding protein 2 precursor 130.
  • IPI00297550 Gene_Symbol F13A1 Coagulation factor XIII A chain precursor 131.
  • IPI00005439 Gene_Symbol FETUB Fetuin-B precursor 132.
  • IPI00064667 Gene_Symbol CNDP1 Beta-Ala-His dipeptidase precursor 133.
  • IPI00018305 Gene_Symbol IGFBP3 Insulin-like growth factor-binding protein 3 precursor 134.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
US12/530,747 2007-03-12 2008-03-12 Mass Spectrometric Quantitation Abandoned US20100167267A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0704764.0A GB0704764D0 (en) 2007-03-12 2007-03-12 Isobarically labelled reagents and methods of their use
GB0704764.0 2007-03-12
PCT/EP2008/052962 WO2008110581A2 (en) 2007-03-12 2008-03-12 Mass spectrometric quantitation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/052962 A-371-Of-International WO2008110581A2 (en) 2007-03-12 2008-03-12 Mass spectrometric quantitation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/697,455 Continuation US20150241443A1 (en) 2007-03-12 2015-04-27 Mass spectrometric quantitation

Publications (1)

Publication Number Publication Date
US20100167267A1 true US20100167267A1 (en) 2010-07-01

Family

ID=37988840

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/530,747 Abandoned US20100167267A1 (en) 2007-03-12 2008-03-12 Mass Spectrometric Quantitation
US14/697,455 Abandoned US20150241443A1 (en) 2007-03-12 2015-04-27 Mass spectrometric quantitation
US15/412,555 Active 2029-04-08 US10976321B2 (en) 2007-03-12 2017-01-23 Mass spectrometric quantitation

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/697,455 Abandoned US20150241443A1 (en) 2007-03-12 2015-04-27 Mass spectrometric quantitation
US15/412,555 Active 2029-04-08 US10976321B2 (en) 2007-03-12 2017-01-23 Mass spectrometric quantitation

Country Status (8)

Country Link
US (3) US20100167267A1 (de)
EP (1) EP2115475B1 (de)
JP (1) JP5468391B2 (de)
AU (1) AU2008225831B2 (de)
CA (1) CA2680373C (de)
ES (1) ES2396163T3 (de)
GB (1) GB0704764D0 (de)
WO (1) WO2008110581A2 (de)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100288918A1 (en) * 2009-05-14 2010-11-18 Agilent Technologies, Inc. System and method for performing tandem mass spectrometry analysis
US20130068943A1 (en) * 2010-05-17 2013-03-21 The Uab Research Foundation General Mass Spectrometry Assay Using Continuously Eluting Co-Fractionating Reporters of Mass Spectrometry Detection Efficiency
WO2013074861A1 (en) * 2011-11-18 2013-05-23 Alnylam Pharmaceuticals, Inc. Quantification of transthyretin and its isoforms
WO2013170067A1 (en) 2012-05-10 2013-11-14 Thermo Finnigan Llc Method for highly multiplexed quantitation of peptides by mass spectrometry and labeling reagent sets therefor
US20140158881A1 (en) * 2011-06-06 2014-06-12 Waters Technologies Corporation Compositions, methods, and kits for quantifying target analytes in a sample
US9366678B2 (en) 2012-10-25 2016-06-14 Wisconsin Alumni Research Foundation Neutron encoded mass tags for analyte quantification
US9399775B2 (en) 2011-11-18 2016-07-26 Alnylam Pharmaceuticals, Inc. RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
WO2016196994A1 (en) 2015-06-03 2016-12-08 President And Fellows Of Harvard College Reagents for quantitative mass spectrometry
US20170117124A1 (en) * 2014-06-13 2017-04-27 DH Technologies Development Pte Ltd. Methods For Analysis of Lipids Using Mass Spectrometry
KR101768098B1 (ko) 2015-01-09 2017-08-16 한양대학교 산학협력단 동중 원소 태그에 기초한 정량적 질량 분석의 잡음을 고려한 펩타이드의 동정 및 정량 방법 및 시스템
US10208307B2 (en) 2015-07-31 2019-02-19 Alnylam Pharmaceuticals, Inc. Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
US10392665B2 (en) 2015-06-19 2019-08-27 Sera Prognostics, Inc. Biomarker pairs for predicting preterm birth
US10955420B2 (en) 2016-09-07 2021-03-23 Mayo Foundation For Medical Education And Research Identification and monitoring of cleaved immunoglobulins by molecular mass
US11209439B2 (en) 2015-09-24 2021-12-28 Mayo Foundation For Medical Education And Research Identification of immunoglobulin free light chains by mass spectrometry
US20220245408A1 (en) * 2021-01-20 2022-08-04 Rutgers, The State University Of New Jersey Method of Calibration Using Master Calibration Function
US20220308066A1 (en) * 2018-10-16 2022-09-29 Dh Technologies Development Pte. Ltd. Multiplexed external calibrator and control for screening and diagnostic assays
US11604196B2 (en) 2014-04-04 2023-03-14 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
US11662351B2 (en) 2017-08-18 2023-05-30 Sera Prognostics, Inc. Pregnancy clock proteins for predicting due date and time to birth
US11806360B2 (en) 2017-09-19 2023-11-07 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
US11946937B2 (en) 2017-09-13 2024-04-02 Mayo Foundation For Medical Education And Research Identification and monitoring of apoptosis inhibitor of macrophage
US11959081B2 (en) 2021-08-03 2024-04-16 Alnylam Pharmaceuticals, Inc. Transthyretin (TTR) iRNA compositions and methods of use thereof

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0704764D0 (en) * 2007-03-12 2007-04-18 Electrophoretics Ltd Isobarically labelled reagents and methods of their use
US8053723B2 (en) 2009-04-30 2011-11-08 Thermo Finnigan Llc Intrascan data dependency
GB0916881D0 (en) * 2009-09-25 2009-11-11 Electrophoretics Ltd Mass labels
WO2011047192A2 (en) 2009-10-14 2011-04-21 Dana-Farber Cancer Institute, Inc. Protected amine labels and use in detecting analytes
JP5432816B2 (ja) * 2010-05-14 2014-03-05 株式会社日立ハイテクノロジーズ 自動分析システムおよび装置管理サーバ
GB201110371D0 (en) 2011-06-17 2011-08-03 Proteome Sciences R & D Gmbh & Co Kg Materials and methods for determining sensitivity potential of compounds
GB201310150D0 (en) 2013-06-07 2013-07-24 Electrophoretics Ltd Methods and compositions relating to alzheimer's disease
GB201310203D0 (en) 2013-06-07 2013-07-24 Electrophoretics Ltd Materials and methods relating to Alzheimer's disease
GB201314485D0 (en) 2013-08-13 2013-09-25 Electrophoretics Ltd Materials and methods relating to pancreatic cancer
EP3041027A4 (de) * 2013-08-30 2017-04-12 Atonarp Inc. Analysevorrichtung
GB201320061D0 (en) 2013-11-13 2013-12-25 Electrophoretics Ltd Materials nad methods for diagnosis and prognosis of liver cancer
GB201410523D0 (en) * 2014-06-12 2014-07-30 Electrophoretics Ltd Mass labels
DE102014224916B4 (de) 2014-12-04 2024-01-18 Bruker Daltonics GmbH & Co. KG Verfahren zur rechnergestützten Analyse eines oder mehrerer Gewebeschnitte des menschlichen oder tierischen Körpers
US20190369112A1 (en) * 2016-11-14 2019-12-05 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Low energy cleavable mass tag for quantitative proteomics
US20200355646A1 (en) * 2019-03-21 2020-11-12 C2Sense, Inc. Systems for detection of volatile ions and related methods
EP4022293A1 (de) * 2019-08-28 2022-07-06 Merck Patent GmbH Optimierte analytderivatisierung zur synergistischen anwendung mit kristallschwammverfahren
EP3786623A1 (de) * 2019-08-28 2021-03-03 Merck Patent GmbH Optimierte analytderivatisierung zur synergistischen anwendung mit kristallschwammverfahren
JP2021173705A (ja) * 2020-04-28 2021-11-01 国立大学法人北海道大学 標的ポリペプチドの情報取得方法および試薬キット
CN112098540A (zh) * 2020-08-31 2020-12-18 首都医科大学附属北京朝阳医院 特征肽段、检测方法及试剂盒
WO2022126026A1 (en) * 2020-12-11 2022-06-16 Calico Life Sciences Llc Methods of protein analysis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031730A2 (en) * 2002-10-03 2004-04-15 Norman Leigh Anderson High sensitivity quantitation of peptides by mass spectrometry
WO2004086050A2 (en) * 2003-03-24 2004-10-07 Xzillion Gmbh & Co. Kg Labelling agents for mass spectrometry comprising tertiary amines
US20060183238A1 (en) * 2005-02-09 2006-08-17 Applera Corporation Amine-containing compound analysis methods
US20100178710A1 (en) * 2005-07-26 2010-07-15 Electrophoretics Limited Mass Labels
US20110111513A1 (en) * 2008-05-23 2011-05-12 Electrophoretics Limited Mass spectrometric analysis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9315847D0 (en) 1993-07-30 1993-09-15 Isis Innovation Tag reagent and assay method
JP2000503845A (ja) 1996-01-23 2000-04-04 ラピジーン，インコーポレイテッド サイジング技術を用いる核酸分子の分析のための方法および組成物
BR9707060A (pt) 1996-01-23 1999-12-28 Rapigene Inc Métodos e composições para detectar o ligamento de par ligante usando indicador não-fluorescente.
DE69701671T3 (de) 1996-01-23 2006-08-17 Qiagen Genomics, Inc., Bothell Verfahren und zusammenstellungen zur sequenzbestimmung von nukleinsäuremolekülen
CA2274587A1 (en) 1996-12-10 1998-06-18 Genetrace Systems Inc. Releasable nonvolatile mass-label molecules
AU725966B2 (en) 1997-01-15 2000-10-26 Xzillion Gmbh & Co. Kg Mass label linked hybridisation probes
GB9815163D0 (en) 1998-07-13 1998-09-09 Brax Genomics Ltd Compounds
JP2000310617A (ja) * 1999-04-28 2000-11-07 Jeol Ltd 質量分析用標準物質及び質量分析用標準物質キット
GB0006141D0 (en) 2000-03-14 2000-05-03 Brax Group Ltd Mass labels
AU8356201A (en) * 2000-08-11 2002-02-25 Agilix Corp Ultra-sensitive detection systems
AU2002323139A1 (en) 2001-08-14 2003-03-03 President And Fellows Of Harvard College Absolute quantification of proteins and modified forms thereof by multistage mass spectrometry
ES2296996T3 (es) * 2001-09-14 2008-05-01 Electrophoretics Limited Marcaje de moleculas.
US20060078960A1 (en) * 2004-05-19 2006-04-13 Hunter Christie L Expression quantification using mass spectrometry
DE602005004902T2 (de) 2005-06-02 2008-10-16 Entelechon Gmbh Künstliches Protein, Verfahren für absolute Quantifizierung der Proteine und seine Benutzung
GB0704764D0 (en) * 2007-03-12 2007-04-18 Electrophoretics Ltd Isobarically labelled reagents and methods of their use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031730A2 (en) * 2002-10-03 2004-04-15 Norman Leigh Anderson High sensitivity quantitation of peptides by mass spectrometry
WO2004086050A2 (en) * 2003-03-24 2004-10-07 Xzillion Gmbh & Co. Kg Labelling agents for mass spectrometry comprising tertiary amines
US20060183238A1 (en) * 2005-02-09 2006-08-17 Applera Corporation Amine-containing compound analysis methods
US20100178710A1 (en) * 2005-07-26 2010-07-15 Electrophoretics Limited Mass Labels
US20110111513A1 (en) * 2008-05-23 2011-05-12 Electrophoretics Limited Mass spectrometric analysis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Thompson et al., "Tandem Mass Tags: A Novel Quantification Strategy for Comparative Analysis of Complex Protein Mixtures by MS/MS," Anal. Chem., 2003, 75 (8), pp. 1895-1904 *
Welti et al., "Lipid species profiling: a high-throughput approach to identify lipid compositional changes and determine the function of genes involved in lipid metabolism and signaling," Current Opinion in Plant Biology, 2004, volume 7, issue 3, pages 337-344. *

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100288918A1 (en) * 2009-05-14 2010-11-18 Agilent Technologies, Inc. System and method for performing tandem mass spectrometry analysis
US8987662B2 (en) * 2009-05-14 2015-03-24 Agilent Technologies, Inc. System and method for performing tandem mass spectrometry analysis
US8658355B2 (en) * 2010-05-17 2014-02-25 The Uab Research Foundation General mass spectrometry assay using continuously eluting co-fractionating reporters of mass spectrometry detection efficiency
US20130068943A1 (en) * 2010-05-17 2013-03-21 The Uab Research Foundation General Mass Spectrometry Assay Using Continuously Eluting Co-Fractionating Reporters of Mass Spectrometry Detection Efficiency
US9768001B2 (en) * 2011-06-06 2017-09-19 Waters Technologies Corporation Compositions, methods, and kits for quantifying target analytes in a sample
US20140158881A1 (en) * 2011-06-06 2014-06-12 Waters Technologies Corporation Compositions, methods, and kits for quantifying target analytes in a sample
US10304670B2 (en) * 2011-06-06 2019-05-28 Waters Technologies Corporation Compositions, methods, and kits for quantifying target analytes in a sample
US20180005808A1 (en) * 2011-06-06 2018-01-04 Waters Technologies Corporation Compositions, methods, and kits for quantifying target analytes in a sample
US9399775B2 (en) 2011-11-18 2016-07-26 Alnylam Pharmaceuticals, Inc. RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
WO2013074861A1 (en) * 2011-11-18 2013-05-23 Alnylam Pharmaceuticals, Inc. Quantification of transthyretin and its isoforms
JP2018021924A (ja) * 2011-11-18 2018-02-08 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． トランスサイレチンおよびそのアイソフォームの定量化
US10570391B2 (en) 2011-11-18 2020-02-25 Alnylam Pharmaceuticals, Inc. RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
WO2013170067A1 (en) 2012-05-10 2013-11-14 Thermo Finnigan Llc Method for highly multiplexed quantitation of peptides by mass spectrometry and labeling reagent sets therefor
US9366678B2 (en) 2012-10-25 2016-06-14 Wisconsin Alumni Research Foundation Neutron encoded mass tags for analyte quantification
US11333669B2 (en) 2012-10-25 2022-05-17 Wisconsin Alumni Research Foundation Neutron encoded mass tags for analyte quantification
US12099065B2 (en) 2014-04-04 2024-09-24 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
US11604196B2 (en) 2014-04-04 2023-03-14 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
US20170117124A1 (en) * 2014-06-13 2017-04-27 DH Technologies Development Pte Ltd. Methods For Analysis of Lipids Using Mass Spectrometry
US10032614B2 (en) * 2014-06-13 2018-07-24 Dh Technologies Development Pte. Ltd. Methods for analysis of lipids using mass spectrometry
KR101768098B1 (ko) 2015-01-09 2017-08-16 한양대학교 산학협력단 동중 원소 태그에 기초한 정량적 질량 분석의 잡음을 고려한 펩타이드의 동정 및 정량 방법 및 시스템
US20230132372A9 (en) * 2015-06-03 2023-04-27 President And Fellows Of Harvard College Reagents for quantitative mass spectrometry
WO2016196994A1 (en) 2015-06-03 2016-12-08 President And Fellows Of Harvard College Reagents for quantitative mass spectrometry
US11982674B2 (en) * 2015-06-03 2024-05-14 President And Fellows Of Harvard College Reagents for quantitative mass spectrometry
US11105810B2 (en) 2015-06-03 2021-08-31 President And Fellows Of Harvard College Reagents for quantitative mass spectrometry
US11169155B2 (en) 2015-06-03 2021-11-09 President And Fellows Of Harvard College Reagents for quantitative mass spectrometry
US10961584B2 (en) 2015-06-19 2021-03-30 Sera Prognostics, Inc. Biomarker pairs for predicting preterm birth
US10392665B2 (en) 2015-06-19 2019-08-27 Sera Prognostics, Inc. Biomarker pairs for predicting preterm birth
US11987846B2 (en) 2015-06-19 2024-05-21 Sera Prognostics, Inc. Biomarker pairs for predicting preterm birth
US11286486B2 (en) 2015-07-31 2022-03-29 Alnylam Pharmaceuticals, Inc. Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
US12049628B2 (en) 2015-07-31 2024-07-30 Alnylam Pharmaceuticals, Inc. Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
US10683501B2 (en) 2015-07-31 2020-06-16 Alnylam Pharmaceuticals, Inc. Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
US10208307B2 (en) 2015-07-31 2019-02-19 Alnylam Pharmaceuticals, Inc. Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
US11209439B2 (en) 2015-09-24 2021-12-28 Mayo Foundation For Medical Education And Research Identification of immunoglobulin free light chains by mass spectrometry
US10955420B2 (en) 2016-09-07 2021-03-23 Mayo Foundation For Medical Education And Research Identification and monitoring of cleaved immunoglobulins by molecular mass
US11662351B2 (en) 2017-08-18 2023-05-30 Sera Prognostics, Inc. Pregnancy clock proteins for predicting due date and time to birth
US11946937B2 (en) 2017-09-13 2024-04-02 Mayo Foundation For Medical Education And Research Identification and monitoring of apoptosis inhibitor of macrophage
US11806360B2 (en) 2017-09-19 2023-11-07 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
US20220308066A1 (en) * 2018-10-16 2022-09-29 Dh Technologies Development Pte. Ltd. Multiplexed external calibrator and control for screening and diagnostic assays
US20220245408A1 (en) * 2021-01-20 2022-08-04 Rutgers, The State University Of New Jersey Method of Calibration Using Master Calibration Function
US11959081B2 (en) 2021-08-03 2024-04-16 Alnylam Pharmaceuticals, Inc. Transthyretin (TTR) iRNA compositions and methods of use thereof

Also Published As

Publication number Publication date
WO2008110581A3 (en) 2008-12-18
US20170146544A1 (en) 2017-05-25
WO2008110581A2 (en) 2008-09-18
ES2396163T3 (es) 2013-02-19
JP5468391B2 (ja) 2014-04-09
US10976321B2 (en) 2021-04-13
ES2396163T8 (es) 2013-04-22
AU2008225831A1 (en) 2008-09-18
CA2680373A1 (en) 2008-09-18
EP2115475B1 (de) 2012-11-28
AU2008225831B2 (en) 2013-05-09
GB0704764D0 (en) 2007-04-18
JP2010520999A (ja) 2010-06-17
CA2680373C (en) 2018-03-27
US20150241443A1 (en) 2015-08-27
EP2115475A2 (de) 2009-11-11

Similar Documents

Publication Publication Date Title
US10976321B2 (en) Mass spectrometric quantitation
US9470692B2 (en) Mass spectrometric analysis
US7449170B2 (en) Materials and methods for controlling isotope effects during fractionation of analytes
US20080145863A1 (en) Affinity selected signature peptides for protein identification and quantification
Steffen et al. Protein species as diagnostic markers
JP5468073B2 (ja) タンパク質の定量方法
US20070243635A1 (en) Method and apparatus for mass spectrometric immunoassay analysis of specific biological fluid proteins
WO2010032458A1 (ja) 新規非アルコール性脂肪性肝疾患バイオマーカーおよび該バイオマーカーを用いた非アルコール性脂肪性肝疾患の検出方法
Yao et al. Quantitative proteomics in development of disease protein biomarkers
Lehmann et al. From “Clinical Proteomics” to “Clinical Chemistry Proteomics”: considerations using quantitative mass-spectrometry as a model approach
RU2673551C2 (ru) Протеотипический пептид q9y4w6-02 и способ масс-спектрометрического анализа содержания afg3-подобного белка человека на его основе
Kotol Sample normalization using SIL standards fornext generation plasma diagnostics
Castillo Mass Spectrometry-Based Approaches for Targeted Quantitative Proteomics in Biomarker Development
Chen Development and Applications of Mass Spectrometric Methods for Proteome Analysis and Protein Sequence Characterization

Legal Events

Date Code Title Description
AS Assignment

Owner name: ELECTROPHORETICS LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHULZKNAPPE, PETER;PIKE, IAN;KUHN, KARSTEN;SIGNING DATES FROM 20090909 TO 20110830;REEL/FRAME:026932/0481

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION